<!DOCTYPE html>
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta content="SAS 9.4" name="generator"/>
<title>SAS Output</title>
<style>
/*<![CDATA[*/
.body.c > table, .body.c > pre, .body.c div > table,
.body.c div > pre, .body.c > table, .body.c > pre,
.body.j > table, .body.j > pre, .body.j div > table,
.body.j div > pre, .body.j > table, .body.j > pre,
.body.c p.note, .body.c p.warning, .body.c p.error, .body.c p.fatal,
.body.j p.note, .body.j p.warning, .body.j p.error, .body.j p.fatal,
.body.c > table.layoutcontainer, .body.j > table.layoutcontainer { margin-left: auto; margin-right: auto }
.layoutregion.l table, .layoutregion.l pre, .layoutregion.l p.note,
.layoutregion.l p.warning, .layoutregion.l p.error, .layoutregion.l p.fatal { margin-left: 0 }
.layoutregion.c table, .layoutregion.c pre, .layoutregion.c p.note,
.layoutregion.c p.warning, .layoutregion.c p.error, .layoutregion.c p.fatal { margin-left: auto; margin-right: auto }
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r p.warning, .layoutregion.r p.error, .layoutregion.r p.fatal { margin-right: 0 }
article, aside, details, figcaption, figure, footer, header, hgroup, nav, section { display: block }
html{ font-size: 100% }
.body { margin: 1em; font-size: 13px; line-height: 1.231 }
sup { position: relative; vertical-align: baseline; bottom: 0.25em; font-size: 0.8em }
sub { position: relative; vertical-align: baseline; top: 0.25em; font-size: 0.8em }
ul, ol { margin: 1em 0; padding: 0 0 0 40px }
dd { margin: 0 0 0 40px }
nav ul, nav ol { list-style: none; list-style-image: none; margin: 0; padding: 0 }
img { border: 0; vertical-align: middle }
svg:not(:root) { overflow: hidden }
figure { margin: 0 }
table { border-collapse: collapse; border-spacing: 0 }
.layoutcontainer { border-collapse: separate; border-spacing: 0 }
p { margin-top: 0; text-align: left }
h1.heading1 { text-align: left }
h2.heading2 { text-align: left }
h3.heading3 { text-align: left }
h4.heading4 { text-align: left }
h5.heading5 { text-align: left }
h6.heading6 { text-align: left }
span { text-align: left }
table { margin-bottom: 1em }
td, th { text-align: left; padding: 3px 6px; vertical-align: top }
td[class$="fixed"], th[class$="fixed"] { white-space: pre }
section, article { padding-top: 1px; padding-bottom: 8px }
hr.pagebreak { height: 0px; border: 0; border-bottom: 1px solid #c0c0c0; margin: 1em 0 }
.stacked-value { text-align: left; display: block }
.stacked-cell > .stacked-value, td.data > td.data, th.data > td.data, th.data > th.data, td.data > th.data, th.header > th.header { border: 0 }
.stacked-cell > div.data { border-width: 0 }
.systitleandfootercontainer { white-space: nowrap; margin-bottom: 1em }
.systitleandfootercontainer > p { margin: 0 }
.systitleandfootercontainer > p > span { display: inline-block; width: 100%; white-space: normal }
.batch { display: table }
.toc { display: none }
.proc_note_group, .proc_title_group { margin-bottom: 1em }
p.proctitle { margin: 0 }
p.note, p.warning, p.error, p.fatal { display: table }
.notebanner, .warnbanner, .errorbanner, .fatalbanner,
.notecontent, .warncontent, .errorcontent, .fatalcontent { display: table-cell; padding: 0.5em }
.notebanner, .warnbanner, .errorbanner, .fatalbanner { padding-right: 0 }
.body > div > ol li { text-align: left }
.beforecaption > h4 { margin-top: 0; margin-bottom: 0 }
.c { text-align: center }
.r { text-align: right }
.l { text-align: left }
.j { text-align: justify }
.d { text-align: right }
.b { vertical-align: bottom }
.m { vertical-align: middle }
.t { vertical-align: top }
.accessiblecaption {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.aftercaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.batch > col, .batch > colgroup > col, .batch > colgroup, .batch > tr, .batch > * > tr, .batch > thead, .batch > tbody, .batch > tfoot { border: none; }
.batch {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    padding: 7px;
    }
.beforecaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.body {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    margin-left: 8px;
    margin-right: 8px;
}
.bodydate {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    text-align: right;
    vertical-align: top;
    width: 100%;
}
.bycontentfolder {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.byline {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.bylinecontainer > col, .bylinecontainer > colgroup > col, .bylinecontainer > colgroup, .bylinecontainer > tr, .bylinecontainer > * > tr, .bylinecontainer > thead, .bylinecontainer > tbody, .bylinecontainer > tfoot { border: none; }
.bylinecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.caption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.cell, .container {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.contentfolder, .contentitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.contentproclabel, .contentprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.contents {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.contentsdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.contenttitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.continued {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    width: 100%;
}
.data {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.dataemphasis {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataemphasisfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataempty {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datafixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datastrong {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.datastrongfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.date {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.document, .errorbanner, .errorcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.errorcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.extendedpage {
    background-color: #ffffff;
    border-style: solid;
    border-width: 1pt;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
    text-align: center;
}
.fatalbanner, .fatalcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.fatalcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.folderaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footer {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.frame {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.graph > col, .graph > colgroup > col, .graph > colgroup, .graph > tr, .graph > * > tr, .graph > thead, .graph > tbody, .graph > tfoot { border: none; }
.graph {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.header {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.headersandfooters, .headerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.index, .indexaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.indexitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.indexprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.indextitle, .linecontent, .list, .list10, .list2, .list3, .list4, .list5, .list6, .list7, .list8, .list9, .listitem, .listitem10, .listitem2, .listitem3, .listitem4, .listitem5, .listitem6, .listitem7, .listitem8, .listitem9, .note, .notebanner, .notecontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.notecontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.output > col, .output > colgroup > col, .output > colgroup, .output > tr, .output > * > tr, .output > thead, .output > tbody, .output > tfoot { border: none; }
.output {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.pageno {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    text-align: right;
    vertical-align: top;
}
.pages {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.pagesdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.pagesitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.pagesproclabel, .pagesprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.pagestitle, .paragraph {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.parskip {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.prepage, .proctitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.proctitlefixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooter {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooteremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooteremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooterempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowfooterstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheader {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderemphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderemphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowheaderstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.systemfooter, .systemfooter10, .systemfooter2, .systemfooter3, .systemfooter4, .systemfooter5, .systemfooter6, .systemfooter7, .systemfooter8, .systemfooter9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: bold;
}
.systemtitle, .systemtitle10, .systemtitle2, .systemtitle3, .systemtitle4, .systemtitle5, .systemtitle6, .systemtitle7, .systemtitle8, .systemtitle9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: medium;
    font-style: normal;
    font-weight: bold;
}
.systitleandfootercontainer > col, .systitleandfootercontainer > colgroup > col, .systitleandfootercontainer > colgroup, .systitleandfootercontainer > tr, .systitleandfootercontainer > * > tr, .systitleandfootercontainer > thead, .systitleandfootercontainer > tbody, .systitleandfootercontainer > tfoot { border: none; }
.systitleandfootercontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.table > col, .table > colgroup > col, .table > colgroup, .table > tr, .table > * > tr, .table > thead, .table > tbody, .table > tfoot { border: none; }
.table {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.titleandnotecontainer > col, .titleandnotecontainer > colgroup > col, .titleandnotecontainer > colgroup, .titleandnotecontainer > tr, .titleandnotecontainer > * > tr, .titleandnotecontainer > thead, .titleandnotecontainer > tbody, .titleandnotecontainer > tfoot { border: none; }
.titleandnotecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.titlesandfooters, .usertext, .warnbanner, .warncontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.warncontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
/*]]>*/
</style>
</head>
<body class="c body">
<div style="padding-bottom: 8px; padding-top: 1px">
<div id="IDX" class="systitleandfootercontainer" style="border-spacing: 1px">
<p><span class="c systemtitle">CVD data set 2</span> </p>
</div>
<div style="padding-bottom: 8px; padding-top: 1px">
<table class="table" style="border-spacing: 1px" aria-label="Data Set REF.CVD_SORTED_2">
<caption aria-label="Data Set REF.CVD_SORTED_2"></caption>
<colgroup><col/><col/><col/></colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="header" scope="col">Title</th>
<th class="header" scope="col">Main_Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="data">HDL and type 2 diabetes: the chicken or the egg?</td>
<td class="data">Based on the current literature, a bidirectional correlation between HDL dysfunction and type 2 diabetes exists, leading to a perpetual self-feeding cycle (Fig. 1). It is increasingly evident that not all HDL disturbances are causatively associated with the development and progression of type 2 diabetes. Most recent clinical and epidemiological data indicate that an optimal range of plasma HDL-C concentrations exists in humans. Even though very high HDL-C levels appear to correlate with dysfunctional HDL, this does not necessarily preclude a substantial benefit when raising ones HDL-C from very low levels to levels within the optimal range. The notion that HDL proteome dictates its lipidome and subsequently HDL particle functionality [11] suggests that alterations in the HDL metabolic pathway have substantial influence on its properties and functions. However, the interrelation between HDL lipidome, proteome and particle functionality is a missing part of the puzzle, which remains as yet unsolved. HDL, the sleeping beauty of lipoproteins, is waiting for its prince to awake her therapeutic potential. Understanding HDL functionality and the factors affecting it in diabetic individuals remains a crucial step towards better glucose homeostasis. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The significance of HDL-C optimal ranges
1. A bidirectional correlation between HDL dysfunction and type 2 diabetes exists.
2. An optimal range of plasma HDL-C concentration exists in humans.
3. Raising one’s HDL-C levels from very low to levels within the optimal range may translate to benefit.
4. HDL proteome dictates its lipidome and HDL particle functionality.
5. Understanding HDL functionality in diabetic individuals remains a crucial step towards better glucose homeostasis. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="data">High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease</td>
<td class="data">Our results add to the growing evidence that ApoB is the primary causal determinant for CAD risk among lipoprotein measurements. (8, 17, 18) XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Cholesterol underlies the development of atherosclerosis. (19) It enters the arterial wall within those ApoB-containing lipoprotein particles that are small enough to enter the tunica intima from the circulation; these particles include small VLDL, IDL and LDL particles as well as lipoprotein(a). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The recent genetic evidence, together with the results in this work, strongly point towards the direction that the lipid content of the particles is secondary to ApoB. (8, 18, 20) These results do not invalidate LDL-cholesterol as a causal risk factor for CAD risk. Indeed, LDL particles contain an apolipoprotein B molecule, as do IDL and VLDL particles. ApoB (in particular ApoB-100) represents the total number of hepatic-derived lipoprotein particles. (21) However, this investigation suggests that the clinical benefit of lowering triglyceride and LDL-C levels is proportional to the absolute change in ApoB. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ApoB measurements are independent of particle density, and are not affected by heterogeneity of particle cholesterol content. (22) This is particularly important for accurately capturing the number of small dense LDL particles, which are believed to be associated with atherosclerosis. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ApoB has been shown to be a superior measure to LDL-cholesterol in the prediction of CAD risk (23) and in prediction of coronary artery calcification. (24) From a clinical perspective, statins target LDL-cholesterol levels rather than ApoB, suggesting that greater benefit might be obtained from lipid-lowering drugs that target lipoprotein particle number. (25) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When analysing data from UK Biobank only, there was also some evidence for triglyceride content measures as an additional risk factor. This was not evident in the main analysis or the sensitivity analysis including data from the earlier CARDIoGRAMplusC4D release. This finding should therefore be interpreted with some caution. There are some caveats to the interpretation of the results of this study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we were able to distinguish between measures of cholesterol content and triglyceride content for some categories of lipoprotein particles, we were not able to distinguish between other lipoprotein measures, such as cholesterol ester and phospholipid content, which correlated almost perfectly with cholesterol content. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
CONCLUSION =&gt; In conclusion, our agnostic investigation to identify risk factors for CAD strongly prioritized ApoB, suggesting that ApoB, representing the number of hepatic-derived lipoprotein particles, is the key determinant of CAD risk among
lipid-related measurements. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This analysis demonstrates the potential of publicly available genetic association data from high-throughput experiments combined with modern data-adaptive statistical learning techniques, for obtaining biological insights into disease aetiology. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="data">Ceramides in Adipose Tissue</td>
<td class="data">The data described in this review and others in this series, identify ceramides as critical lipid metabolite that modulate adipose tissue function, homeostasis, and contribute to metabolic
disease. Moreover, interventions that reduce ceramide synthesis in adipose tissue, delay, or prevent various comorbidities of obesity, such as insulin resistance and liver steatosis. These discoveries, while exciting, raise several essential questions to be answered to validate ceramide as a potential therapeutic target. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, can additional mechanisms be identified to explain ceramide action? Although initial studies identified a couple of key mechanisms (i.e., regulation of Akt) for ceramide actions, the numerous effects (e.g., regulation of thermogenic program, mitochondrial function) elicited by ceramide seems unlikely to be fully explained solely by PP2A-Akt axis or PKCz-Akt axis. Therefore, identifying additional molecular mechanisms will be crucial for understanding the roles of ceramides such that the therapeutic strategy could be developed accordingly. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, what is the role of immune-cell ceramide content in maintaining adipose tissue homeostasis? How do ceramides regulate these cell populations and how do they interact with adipocytes to gauge nutrient content? XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, how do b-adrenergic’s inhibit ceramide synthesis in adipose tissue? Delineation of the molecular targets downstream of the b-adrenergic receptor may offer additional interventional strategies to target ceramide synthesis. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fourth, are there additional regulators (nutrients / enzymes) that modulate intracellular ceramide content? The recent development of the ceramide flux assays coupled with secondary biochemical assays might favor the identification of more regulators and lead to additional strategies to safely target ceramide synthesis for its therapeutic use. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fifth, how various enzymes in sphingolipids synthesis and degradation pathways coordinate to maintain lipid homeostasis, particularly in response to various local and systemic stimuli. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="data">Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study</td>
<td class="data">This biomarker study showed inverse associations of baseline plasma n-3 fatty acids and DHA with the risk of macrovascular events and for n-3 fatty acids with the risk of death among individuals with type 2 diabetes. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These inverse associations appeared approximately linear, and among the macrovascular events, n-3 fatty acids and DHA demonstrated stronger associations with cardiovascular death and non-fatal stroke. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, no significant associations were observed for the predominant fatty acids such as n-6 fatty acids, LA, MUFA and SFA with the risk of macrovascular events and death, after adjustment for multiple traditional risk factors. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The prospective associations of circulating n-3 fatty acids and DHA with the risk of CVD are consistent with the prior studies. According to previous pooled analyses, DHA in whole plasma was associated with a lower risk of fatal and non-fatal CHD (RR [95% CI]: 0.78 [0.69, 0.90] and 0.91 [0.84, 0.98], respectively) in people without a history of CVD [9]. In addition, another study reported that plasma n-3 fatty acids were associated with a lower risk of non-fatal myocardial infarction [21]. Similar inverse associations with CHD and stroke were observed in other studies which measured n-3 fatty acids in plasma phospholipid [10, 22–24], whole blood [25] and serum [26], among people without prior CVD. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These studies did not assess the C statistic and NRI; however, the present study did not detect significant improvement in predicting macrovascular events by adding n-3 fatty acids or DHA into the model including traditional cardiovascular risk factors. This indicates that the predictive power of plasma n-3 fatty acids and DHA may be limited in the presence of a complement of traditional cardiovascular risk factors. On the other hand, cardiovascular benefits of high-dose supplementation with n-3 fatty acids were recently observed in REDUCE-IT, where there were potentially greater benefits of n-3 fatty acid supplementation in those with lower plasma levels of n-3 fatty acids. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to generally consistent results from observational studies of circulating n-3 fatty acids and DHA, the effects of n-3 fatty acid supplementation on cardiovascular outcomes in RCTs have been mixed [4, 6, 27–30]. The recent study, A Study of Cardiovascular Events in Diabetes (ASCEND) trial, of 15,480 individuals with diabetes free of prior CVD, which tested n-3 fatty acid supplementation (1 g/day) for 7.4 years, did not lower the risk of composite major vascular outcomes, while only vascular deaths were less frequent in the supplementation group than in the placebo group (RR 0.82 [95% CI 0.68, 0.98]) [31]. On the other hand, the recent AHA science advisory has suggested that the use of n-3 fatty acid supplementation was probably justified in individuals at high cardiovascular risk [8, 28]. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In REDUCE-IT, which used high-dose (4 g/day) n-3 fatty acid supplementation in 8179 individuals with established CVD or with diabetes and other risk factors, the risk of composite cardiovascular outcomes was substantially reduced (HR 0.75 [95% CI 0.68, 0.83]) [7]. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, some secondary analyses from large trials have reported the benefit of n-3 fatty acid supplementation on CVD in diabetic populations with hypercholesterolaemia [32], chronic heart failure [33] and history of myocardial infarction [34]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further investigation of the benefits of n-3 fatty acid supplementation will, therefore, be required among people with type 2 diabetes and high CVD risks. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several mechanisms may explain the favourable associations between n-3 fatty acids and the risk of CVD. Previous clinical trials looking at intermediate cardiovascular outcomes among people with diabetes have reported that n-3 fatty acid supplementation could lower triacylglycerol concentrations [35, 36], improve arterial blood flow and attenuate inflammatory signals [37, 38]. These effects were supported by clinical trials in the general population and in experimental studies [39–41]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The present study observed the inverse associations between baseline plasma n-6 fatty acids and LA with the risk of death, but these associations attenuated after adjustment for multiple risk factors. Similar findings have been reported between serum LA and mortality in a cohort of older adults (≥65 years of age) [42]. We did not, however, detect significant associations between n-6 fatty acids and LA with the risk of macrovascular events. These results were consistent with those of previous observational studies [23, 24, 43] and directionally concordant with the recent pooled analyses of 30 cohort studies which reported that higher circulating and tissue levels of LA were associated with a lower risk of major cardiovascular events (HR 0.93 [95% CI 0.88, 0.99]) [44]. In addition, our study did not detect significant associations with the risk of CVD for circulating MUFA and SFA, which is consistent with previous studies [24, 43, 45], while some studies have reported that MUFA in blood were associated with a higher risk of CVD [46]. There were no significant associations between any fatty acids and the risk of microvascular events. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further analysis specifically for renal outcome also demonstrated no significant associations. Although limited studies have assessed the association between circulating fatty acids and renal outcomes, in an Italian cohort of 931 adults, plasma n-3 fatty acids were inversely associated with the risk of developing renal insufficiency (creatinine clearance rate &lt;60 ml/min) [47]. However, in a cohort of 2792 individuals, levels of n-3 and n-6 fatty acids and SFA in plasma phospholipid were not associated with kidney function [48]. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  CONCLUSIONS =&gt; In conclusion, we report distinct associations of different plasma fatty acids with the risk of major clinical outcomes in individuals with type 2 diabetes. In particular, plasma n-3 fatty acids were associated with a lower risk of macrovascular disease and death, and DHA was associated with a lower risk of macrovascular disease. These results support the cardioprotective effects of n-3 fatty acids and DHA and further merit testing the role of high-dose n-3 fatty acid supplementation in individuals with type 2 diabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="data">Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes</td>
<td class="data">In this study, we investigated associations between plasma metabolites and kidney function (cross-sectionally and longitudinally) in individuals with T2D. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The key findings include several novel associations between eGFR and circulating amino acids, TGs, lipids in VLDL sub-classes, free fatty acids, and lipids in HDL subclasses cross-sectionally. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX eGFR slopes associated with tyrosine and subclasses of HDL lipoproteins (before correction for multiple testing). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX None of the metabolites measured were significantly associated with urinary albumin excretion. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These findings are in line with results from a recent study in type 1 diabetes where metabolites were mainly associated with eGFR and not albuminuria (29). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The AAA phenylalanine was strongest inversely associated with eGFR levels, followed by the BCAA isoleucine and the polar amino acid glutamine. This result replicates findings from a recent study by Barrios et al, where a strong inverse cross-sectional association between phenylalanine and eGFR was demonstrated both in 926 individuals with T2D and 4838 individuals without diabetes, after adjusting for age, sex, BMI, statin use, and hormone replacement therapy (18). Barrios et al did not find an association between phenylalanine and longitudinal changes in eGFR, similar to the findings in this study. Higher phenylalanine and lower tyrosine levels due to impaired renal conversion of phenylalanine have previously been reported in renal disease (30,31). In our study, a positive association between tyrosine and eGFR was also observed cross-sectionally and longitudinally. Recently, the results of ADVANCE trial in 3587 individuals with T2D demonstrated a positive association of phenylalanine with macrovascular diseases and all-cause mortality; however, this was attenuated after adjustment for cardiovascular risk factors. Moreover, this study showed an inverse association between tyrosine and microvascular complications (17). XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This trial demonstrated that higher levels of aromatic (histidine) and branched-chain (leucine) amino acids were associated with a lower risk of all-cause mortality. This is in line with our findings in which histidine and leucine were inversely associated with eGFR. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a study by Niewczas et al comparing T2D progressors (n = 40) to ESRD and non-progressors (n = 40), higher levels of phenylalanine, tyrosine, and leucine were associated with a lower risk of  progression to ESRD during 12 years follow-up, albeit the results were not statistically significant after adjustment for HbA1c, albumin excretion, eGFR, and multiple testing (32). XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, we previously reported that higher glutamine was most significantly associated with having an HbA1c &lt; 53 mmol/L (33). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this study, eGFR was inversely associated with TGs, lipid measures in VLDL subclasses, sphingomyelin, and fatty acids like omega-6 and linoleic acid but positively associated with lipid measures, except TGs, in HDL sub-classes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This inverse relationship is in line with results in both individuals with and without diabetes from the previously mentioned study by Barrios et al (18). The associations between these lipid measures and longitudinal endpoints of ESRD and macro- or microvascular complications have to our knowledge not been tested in any study in people with T2D. We identified the lipids in HDL to be associated positively with longitudinal eGFR slopes among T2D, which became non-significant after FDR correction. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These could be correct signals reflecting cross-sectional results on eGFR in our study. The longitudinal results in our study may have missed the multiple testing threshold due to lower statistical power (n = 1100) compared to cross-sectional meta data where we had 3089 individuals.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX On the other hand, we cannot undermine the possibility of inter-metabolite relatedness as suggested by the sensitivity analysis (correlation heatmap) that may reduce the number of tests. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, in a longitudinal study by the FinnDiane Study Group including 3544 individuals with type 1 diabetes, the TG–cholesterol imbalance was associated with progression in albuminuria and all-cause mortality, as was a large HDL cholesterol (14). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous studies in large cohorts of dyslipidemia and DKD have demonstrated associations between routinely measured higher TG and lower HDL cholesterol levels to the progression of DKD in individuals with T2D (39,40). Higher TG and lower HDL cholesterol are clinical components of the metabolic syndrome and may also be consequences of the underlying insulin resistance (41). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Targeting HDL cholesterol or phospholipids may be a future therapeutic approach, although previous clinical studies with HDL cholesterol increasing agents—for example, torcetrapib (42) in high-risk individuals of cardiovascular disease—have demonstrated increased risk of mortality and morbidity of unknown mechanism. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a small study by Drew et al (n = 13), intravenous reconstituted HDL infusion in patients with T2D increased plasma insulin. It activated adenosine 5′-monophosphates–activated protein kinase in skeletal muscle when compared to placebo (43). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSION =&gt; In conclusion, the current largest-to-date study identifies metabolites associated with an impaired eGFR among individuals with T2D while none of the metabolites measured were significantly associated with urinary albumin excretion.  XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These results suggest that cholesterol and phosphoglycerides in HDL subclasses may be associated with a better kidney function while high levels of several amino acids and fatty acids, lipids in VLDL sub-classes, and TGs in all lipoproteins are associated with an impaired kidney function. The findings suggest alterations in the metabolome associated with renal impairment in T2D of primary importance in non-albuminuric DKD or the early stages of disease before development of albuminuria. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="data">Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies</td>
<td class="data">In the frame of the PREDIMED trial we found that XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) baseline lysine and especially 2-AAA circulating levels were associated with future risk of T2D but not with CVD risk; XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) a baseline diabetic status appeared to modify the association between baseline lysine levels and subsequent CVD risk so that only subjects who were diabetic at baseline exhibited an association between higher lysine levels and increased risk of future CVD; XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (3) 1-year changes in lysine, 2-AAA and pipecolic acid were not associated with subsequent CVD or T2D risk; XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (4) the MedDiet did not show any significant effect on 1-year changes neither in 2-AAA nor in lysine; XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (5) the MedDiet supplemented with nuts or with EVOO may be reducing CVD or T2D risk through the regulation of different biological mechanisms than those related to lysine degradation. However, MedDiet may be modifying the risk conferred by high levels of metabolites included in the lysine degradation pathway. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A previous work published by Wang et al. [5], found in two independent cohorts—Framingham Heart Study (FHS)-Offspring Cohort and Malmö Diet and Cancer Study (MDC)-Cardiovascular Cohort-that high 2-AAA predicted the risk of developing T2D in normoglycemic individuals.  XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our results confirmed this association among subjects at high cardiovascular risk showing that the higher the baseline levels of 2-AAA, the higher the subsequent T2D risk in this Mediterranean population. This is an important replication and update of the results considering that all PREDIMED participants randomly selected for the T2D case-cohort were at high risk of developing CVD and had baseline glucose levels that can be considered as a proxy of a pre-diabetic status. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our findings suggest that it seems possible to predict the risk of developing diabetes conferred by 2-AAA even at a pre-diabetic stage. We found similar results for the association of lysine with T2D but this association was not as robust as that for 2-AAA. A recent small cross sectional study reported that 2-AAA was also associated with obesity and metabolic syndrome in addition to T2D [3]. Consistent with our results, they also reported that lysine presented similar but weaker associations with these metabolic conditions. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A mechanism potentially explaining these associations may be that 2-AAA is elevated in response to high glucose levels, leading to increased insulin secretion and promoting mechanisms involved in maintaining glucose homeostasis in early stages of insulin resistance [5]. In the case of lysine, it may be elevated at an early stage of this pathophysiological process to provide the 2-AAA substrate for a likely compensatory mechanism [3]. In concordance with these explanations, lysine was also found to be a predictor of insulin resistance and gestational diabetes during pregnancy in a previous study [18]. Moreover, both 2-AAA and pipecolic have been found to be elevated in diabetic corneas suggesting that this pathway may be also related to diabetes induced diseases [6]. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX On the other hand, we observed no association between baseline lysine, 2-AAA or pipecolic acid levels and subsequent incidence of CVD in non-diabetic subjects. However, the association of lysine with CVD was present in subjects with an initial diabetic status. Therefore, it is likely that this association may only be apparent among subjects with pre-existent T2D. In this context, diabetic status may behave as an effect modifier of the association between lysine and CVD. The p value for the interaction test was statistically significant, supporting this interpretation. This finding represents a novelty and deserves future replication in further independent cohorts. It can be speculated that this effect modification by pre-existent diabetes may suggest that lysine can be implicated in the development of complications associated with T2D, because high levels of lysine may represent a biomarker of a poorer control of glycemic levels in T2D. This interpretation should be taken with caution and further confirmation is needed. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition to the 2-AAA pathway of lysine degradation, L-homoarginine may be also synthesized from lysine catabolism and, this alternative pathway, involving arginine and nitric oxide synthesis [19, 20], may be related to CVD and T2D, as we have previously reported [21, 22]. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Regarding the effect of the dietary intervention, we observed no effect of MedDiet on lysine, 2-AAA or pipecolic acid 1-year changes. Additionally, we did not find any significant multiplicative interaction between the MedDiet intervention and 1 year changes in lysine, 2-AAA or pipecolic acid. However, we found that Med-Diet may be modifying the effects of baseline lysine on CVD risk as we found a significant interaction between lysine and the intervention. In the same direction, results on 2-AAA and pipecolic acid pointed at the same effect of MedDiet + EVOO (non significant interaction). These results may be suggesting that although there is no  direct effect of diet on the levels of the metabolites, it is possible that MedDiet may be modifying the effects of metabolites on CVD or T2D risk by affecting other mechanisms that may involve different metabolic pathways, inflammation or oxidation.   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In conclusion, our results provide an interesting independent replication of the association of 2-AAA with future risk of T2D, a similar association for lysine and pipecolic acid and a suggestion of a diabetes-dependent association of lysine with subsequent CVD risk. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="data">Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease</td>
<td class="data">In this study of over 7000 participants from three prospective population-based cohorts, we present the metabolic signature of atherosclerosis offering insights into the widespread systemic disturbances underlying atherosclerosis. Atherosclerosis was associated with disturbances of inter-connected pathways related to lipid, fatty acid and carbohydrate metabolism, BCAA and aromatic acid metabolism, TCA and urea cycle, and muscle metabolism and showed a largely consistent pattern between coronary and carotid atherosclerosis. Subsequently, these metabolites were also associated with incident CVD events highlighting the importance of these pathways in progression to clinical CVD. The fact that the majority of these associations attenuated substantially after adjustment for conventional CVD risk factors suggests that these metabolites lie on pathways closely associated with CVD risk factors. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Beyond KEGG pathways, replicated metabolites highlight oxidative stress and inflammatory pathways. For example, 5-oxoproline and glutamate, both inversely associated with CAC and IMT, are involved in both synthesis and degradation of glutathione. Glutathione deficiency contributes to oxidative stress, which plays a key role in the pathogenesis of atherosclerosis. (38, 39) N-acetylneuraminic acid, positively associated with CAC and IMT, is the major form of sialic acid in mammals and serves as a biomarker of a sustained inflammatory response with subsequent effects on atherosclerosis. (39, 40) Glycoprotein acetyls have previously shown associations with risk of MI and stroke, (41) and here, we also report consistent effects with CAC and IMT. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, lactate, also associated positively with IMT, formed from pyruvate under insufficient oxygen supply (hypoxia), is an indicator of inflammation. Local hypoxia can occur in highly active inflamed tissues where demands from increased cellularity exceed oxygen supply, a feature of atherosclerotic plaque. (42) Hypoxia has been hypothesized to stimulate pro-atherosclerotic processes, including deficient lipid efflux, inflammation, interference with macrophage polarization and glucose metabolism. (43) XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The four metabolites linked to sugar and carbohydrate metabolism (D-glucose, 1,5-anhydrosorbitol, D-mannose, and myo-inositol) were all directly associated with both CAC and/or IMT after adjustment for CVD risk factors. 1,5-anhydrosorbitol, a marker of glycaemic control, has previously been associated with CVD and kidney disease and highlights the close association of atherosclerotic disease, diabetes and insulin resistance. (38, 44, 45) Mannose has repeatedly been associated with pre-diabetes, incident Type 2 diabetes, (46) and all-cause mortality, (47) and here, we highlight associations with atherosclerosis and incident CVD, independent of glucose. In this regard, mannose showed stronger correlations with lipids and N-acetylglycoproteins than with glucose (Figure 4). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Mannose has a central role in glycation processes of lipoproteins that in turn may play a role in the initiation and development of atherogenesis. N-glycans are up-regulated in pro-inflammatory settings and have been found on the  cell surface in early stages of atherosclerotic plaque development. (48) Taken together these data suggest that mannose could also affect CVD risk through non-glucose dependent pathways. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Energy metabolism, TCA cycle and glycolysis, were also central pathways associated with atherosclerosis. Alanine is synthesized directly from pyruvate, a product of glycolysis,which can supply the cells with energy through the TCA cycle in aerobic conditions. Increased glucose utilization has been shown in high-risk atherosclerotic plaques. (49) In turn, citrate is an intermediate and key energy metabolite in the TCA cycle and has previously been associated with cardiovascular mortality. (50) Reduced oxygen levels in presence of atherosclerosis may affect the TCA cycle since it is oxygen dependent. Creatine, an amino acid derivative, reflects changes of energy metabolism in the muscles; it is transported through the circulation and taken up by tissues with high energy demands, with creatinine as a degradation product. Their levels have been inversely associated with fat intake in animal studies. (51, 52) XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The lipoprotein profiles analyses confirmed previous observations investigating the associations of these lipids with subclinical atherosclerosis, (53) MI, and stroke. (41) Here, we further show a largely consistent picture between coronary and carotid atherosclerosis and with cardiovascular events. Association of triglycerides with atherosclerotic disease and future events was positive even within HDL particles in support of previous observations. Conversely, not all HDL cholesterol was inversely associated with atherosclerosis highlighting the fact that causal association of HDL with lower CVD risk may be limited to certain particles (i.e. not the ones containing triglycerides).  XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, LDL and VLDL was consistently positively associated with higher CAC and IMT and higher risk of CVD events with a small trend showing stronger associations with decreasing density of lipoproteins. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The molecular interaction gene network map (Supplementary material online, Figure S6) further depicts the interconnections between inflammatory, insulin, and lipid pathways reflected by metabolite markers of atherosclerosis. For example, the network includes fibronectin 1 (FN1), which is involved in cell adhesion and migration processes including wound healing, blood coagulation, and host defence; genetic polymorphisms within this gene have been associated with adverse lipid levels and coronary heart disease. (54, 55) Other examples include CCAAT/enhancer-binding protein beta, a master regulator of immunity and inflammation, other immunity related genes (e.g. PI3K complex), and pathways related to betaine-homocysteine metabolism (BHMT), glycolysis (pyruvate kinase), and angiogenesis (ANGPT4).  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX       CONCLUSIONS =&gt; In summary, in this study of over 7000 participants from three prospective population-based cohorts, we found strong associations between serum metabolites observed on 1H NMR spectroscopy and subclinical atherosclerosis which was largely consistent between the two vascular beds (coronary and carotid arteries). XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our metabolic and gene networks reveal highly interconnected system level metabolic disturbances in atherosclerosis, much of which overlaps with the known cardiovascular risk factors. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="data">Assessing the causal association of glycine with risk of cardio-metabolic diseases</td>
<td class="data">Based on a genetic discovery in up to 80,003 participants from five studies, we identify 22 loci not previously reported for glycine. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Two novel loci (PSPH and PHGDH) are located in genes encoding enzymes catalysing the de novo biosynthesis of serine—a pathway which has not previously been genetically associated with glycine, despite the close metabolic link between glycine and
serine. We also identified two rare variants (in FGG and near KIF5B) not previously reported for metabolic traits, which corroborates previous evidence that rare genetic variation plays a role in amino acid levels (13). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Based on four genetic scores with different degrees of specificity to the glycine pathway, we demonstrate that low levels of glycine are genetically associated with higher risk of CHD, which supports a potential protective role of glycine against CHD. The effect size differs depending on the genetic score, with estimated effects of glycine on CHD increasing with the degree of specificity of the genetic score to glycine, which strengthens the evidence that the observed genetic associations are driven by glycine. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We furthermore found that glycine has similarly protective effects in men and in women, which contradicts findings by Hartiala et al., (7) who suggested that the sex-specific association of CPS1 with CHD may reflect a causal role for glycine on CHD in women only. We however show that, after taking into account the sex-specific effect sizes on glycine, the genetic association of glycine with CHD, based on CPS1 only and the four genetic scores for glycine, is similar in magnitude in both sexes. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our findings suggest that the inverse genetic association of glycine with blood pressure may at least partly explain the genetic glycine-CHD association. High blood pressure is a major risk factor for cardiovascular diseases (29) and glycine supplementation has been shown to lower blood pressure in rodents (30–32) and in one small intervention study on human participants (33). Our findings corroborate a potential blood pressure-lowering effect of glycine for the first time in a large-scale epidemiological setting. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A proposed mechanism through which glycine may lower blood pressure is by the glycine-gated chloride channels expressed on the endothelial surface, which upon binding of glycine induce membrane hyperpolarisation and thus the production of nitric
oxide—a well-known vasodilator (34). Despite the strong genetic association of glycine with blood pressure, we cannot conclude that the genetic effect of glycine on CHD risk is entirely mediated through blood pressure, due to the limited power of the multivariable MR analyses. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Moreover, the absence of associations between glycine and stroke, for which hypertension is also a major risk factor (29), suggests that there also may be other physiological pathways through which glycine influences cardiovascular disease risk. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We however find no evidence for a role of glycine in lipid metabolism or blood cell traits, despite previous studies suggesting that glycine may regulate lipid metabolism (2) and platelet (35) and immune cell activation (36). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX There may be other mechanisms underlying the genetic glycine-CHD association which we could not investigate here. For example, glycine may protect against oxidative stress, as it is a substrate for the biosynthesis of glutathione—a major antioxidant in human cells (37, 38). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX While multiple observational epidemiological studies have linked high glycine levels to lower incidence of T2D (3, 4, 39), the genetic evidence for causality is weaker. MR analyses based on the larger but less specific genetic scores indicate no causal effect of glycine on risk of T2D, while variants in genes related to glycine catabolism drive associations of the 5 and 2 SNP scores with lower T2D risk. These findings suggest that overall levels of glycine may not be causal for T2D but that low glycine levels due to changes in the catalytic efficiency of the glycine cleavage system—the protein complex that catalyses the major catabolic pathway of glycine (40)—may cause higher risk of T2D. Coding mutations in genes of the glycine cleavage system have been identified as one of the causes of severe hyperglycinemia (41), a life-threatening inborn error of metabolism, and have been linked to higher risk of neural tube defects (42). To the best of our knowledge, this enzyme complex has not previously been linked to common cardio-metabolic diseases. An alternative interpretation of our findings is that overall glycine levels are causally associated with T2D risk, but that this association is masked by pleiotropic effects of CPS1. As CPS1 had a 10-fold stronger effect on glycine than most other glycine-associated variants, the genetic scores which included CPS1 in fact mostly represented CPS1. The CPS1 locus has widespread effects across the metabolome, which are not restricted to the glycine pathway, and has also been associated with other traits, of which some, including glycine, may protect against T2D while others could increase T2D risk. Therefore, the null-association based on the genetic scores including CPS1 may have been driven by glycine-independent pathways and may thus mask a true genetic association of glycine with T2D. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our findings do not entirely replicate the recently reported protective effect of glycine on T2D based on an MR analysis using five loci for glycine (3). The significant inverse genetic association of glycine with T2D risk reported by Merino et al. was largely driven by CPS1, of which the glycine-raising allele was nominally associated with lower T2D risk in the 11,600 T2D cases and 33,000 controls. Our analyses based on 74,124 T2D cases and 824,006 controls did not replicate the nominal association with T2D for CPS1, nor for the genetic scores that included CPS1. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We find strong genetic evidence that low glycine levels are a consequence of IR, which suggests that the inverse association of glycine levels with incidence of T2D is at least partly driven by IR. Observational epidemiological research has previously described that measures of IR are inversely associated with glycine (43, 44) and rodent experiments suggest that increased oxidative stress caused by IR leads to a higher rate of glutathione synthesis, which may lead to glycine depletion (45). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another proposed mechanism that could link IR to lower levels of glycine is the increased demand for glycine to safely excrete fatty acyl-CoA esters which accumulate as a consequence of incomplete suppression of lipolysis and resulting high circulating levels of fatty acids in the insulin resistant state (46). Free fatty acids can lead to a build-up of beta oxidation intermediates, i.e., fatty acyl-CoA esters, which can upon trans-conjugation with glycine be safely excreted as fatty acyl-glycine (46, 47). XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our findings raise the question whether glycine supplementation merits evaluation as a strategy to prevent cardio-metabolic disease. A variety of glycine supplements are available for purchase “over the counter” and are used without clinical follow-up for a wide range of indications. To consider the preventive value, the potential benefits and harms should be assessed. Effect sizes for CHD varied depending on the “specificity” of the genetic score and, in addition, CI across these estimates varied, ranging from 0.69 to 0.98 per SD higher glycine levels. However, the increase in the effect estimate of glycine with increasing specificity of the genetic score suggests that the benefit may be considerable. This, together with the feasibility of achieving the required glycine concentration in blood given its short half-life (48), and any potential harms arising, require piloting under controlled conditions. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In terms of safety, in vitro and animal-based evidence has suggested that glycine and serine may promote oncogenesis by fuelling one-carbon and folate metabolism (49). This is indirectly supported by a suggestive association between folic acid supplementation and cancer incidence (50). Furthermore, it was recently shown that a serine and glycine-depleted diet improves treatment response and survival in murine models of colorectal cancer and lymphoma (51). Our genetic analyses of three site-specific cancers where GWAS summary statistics were available to provide maximum power and specificity did not provide evidence that glycine levels increase the risk of breast, ovarian or prostate cancer. However, consortia data for other cancer sites and types are required to provide genetic evidence against an increased risk for site-specific cancers other than breast, ovarian and prostate, and a thorough assessment of the potential carcinogenicity of glycine is required before glycine supplementation can be considered even in an evaluative setting in human participants. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our investigation into the aetiological role of glycine metabolism in cardio-metabolic diseases has several strengths. The variance in glycine levels explained by the genetic score comprising 24 loci was more than 15%, which enabled us to conduct well powered MR experiments. The high proportion of explained variance can be attributed to the biological specificity of the exposure. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Secondly, we conducted a thorough assessment of pleiotropic effects of the genetic scores for glycine and generated a series of subsets of the full genetic score with increasing specificity to glycine metabolism, in order to reduce the likelihood of contributions of glycine-unrelated metabolic pathways to the causal effect estimate. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We adopted multiple MR approaches, including robust methods which are less sensitive to bias due to pleiotropic effects by a subset of genetic variants within the score (52–54), which further decreases the chance that the genetically determined effect estimate was driven by glycine-independent pathways.  XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSION =&gt; In conclusion, we show that low glycine is associated with higher incidence of CHD and that genetic scores for glycine are compatible with this relationship being causal. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We furthermore show that a glycine-lowering effect of IR may drive the consistently reported association between higher glycine and lower incidence of T2D, while the evidence for a causal relationship between glycine and T2D risk is weaker. XXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="data">Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis</td>
<td class="data">Targeting the resolution of inflammation represents a novel therapeutic strategy that could significantly reduce the global health burden associated with (diabetes accelerated atheroscelerosis) DAA. This approach is based on the postulate that strategies that promote the resolution of inflammation, such as with drugs including the LXs ,will lead to reduced end-organ damage in conditions such as diabetic complications. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Interestingly, it has recently been demonstrated that circulating levels of aspirin-triggered LXA4 (15-epi-LXA4) are lower in patients with diabetic kidney disease versus non-diabetic kidney disease, hinting at a resolution deficit in patients with diabetic complications (34). We have shown for the first time the protective effects of LXs on vascular complications in the STZ-induced diabetic ApoE2/2 mouse, a murine model with features of human type 1 diabetes (hyperglycemia and insulin deficiency), ultimately leading to DAA. In addition to endogenous LXA4, we evaluated the therapeutic potential of a synthetic (1R)-stereoisomer analog (Benzo-LXA4), generated through modification of the LXA4 triene unit. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, the Benzo-LXA4 analog exerted similar actions to LXA4, resulting in attenuated atherosclerotic plaque development. To date, no studies have directly addressed the potential role of LXs as a novel therapeutic agent to reduce CVD independent of the effects on lipids, glycemic control, and/or thrombosis. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Typically, vascular lesions first develop in this murine model in the aortic root and carotid arteries at 8–10 weeks of age, with more advanced lesions evident at 15 weeks (35,36). This murine model recapitulates important features of human type 1 diabetes (i.e., hyperglycemia and insulin deficiency). Here we report that blood glucose and lipid levels are unchanged by LXs in non-diabetic and diabetic mice, indicating that the protective effects of LXs are not exerted via direct control of glycemia or circulating lipid levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, LXs attenuated the progression of DAA, inflammation, and vascular dysfunction. Crucially, the atheroprotective effect of LXs was also observed in diabetic ApoE2/2 mice that were administered these drugs 10 weeks after the disease was established, emphasizing the utility of this therapeutic approach in subjects with established CVD, arguably the most common clinical scenario in human subjects with diabetes. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is noteworthy that the protective effect of LXs was only observed in the setting of diabetes, with no obvious effect seen in non-diabetic mice. These data would indicate that LX action is only potentiated in the setting of chronic inflammation, as observed in our diabetic mice. This is in keeping with the concept that endogenous pro-resolving lipid mediators, such as LXs, are typically released at the sites of inflammation, after the inflammatory response has initiated. Furthermore, It is likely that in our study, after the delivery of LXs to these mice, the inflammatory milieu seen in diabetic mice provides increased ALX/FPR2 receptor availability as a result of infiltrating leukocytes, providing the necessary machinery for LX action. In keeping with this, we show that Alx/fpr2 expression is markedly increased in aortic tissue from diabetic mice versus non-diabetic controls, along with suggestive evidence of increased Alx/fpr2 expression in carotid plaque tissue from patients with diabetes versus those without diabetes that further supports this hypothesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data suggest that the underlying mechanism for LX-mediated atheroprotection occurs via regulation of (platelet derived growth factor) PDGF and TNF-a signaling in vascular cells. Excessive proliferation of vascular (smooth muscle cells) SMCs, macrophage infiltration, and (endothelial cells) EC dysfunction are recognized as key components of the development and progression of atherosclerosis (37). At the cellular level, our data indicate an important role for LXs in regulating PDGF-mediated SMC migration and proliferation, TNF-a–mediated NF-kB activation, and EC-monocyte interactions. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We and others (38,39) have previously demonstrated that LXs exert effects on macrophages, promoting a macrophage M1-M2 switch and inhibiting macrophage apoptosis. In this model of diabetes mediated atherosclerosis, we noted a significant increase in the expression of pan-macrophage markers cd11b and f4/80 in diabetic aortic tissue, with no increase in diabetic mice administered LXs. However, we find no compelling evidence to suggest that there is a shift from M1 to M2 phenotype in response to LX treatment in this specific model; rather, the data indicate an LX-mediated effect on overall macrophage content. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In order to determine whether these molecular and cellular actions were also relevant to the human context, we further evaluated the role of endogenous LXA4 ex vivo on human plaque lesions. LXA4 exerted maximal effect within the 10–100 nmol/L range, with an attenuation of effect observed at the higher LXA4 concentration (1 mmol/L). This dose-response effect is in keeping with previous studies (40–42) indicating that there is a therapeutic window for LXA4. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Among the cytokines strongly modulated by LXA4, secretion of the glycoprotein granulocyte-macrophage colony-stimulating factor (GMCSF) was increased in response to LPS and reduced by LXA4. Several cytokines were released at high levels from ex vivo–treated human plaque tissue and remained unperturbed by LPS and LXA4, including IL-6, IL-8, and CRP. This is not unexpected, given that the nature of the diseased tissue. It is possible that longer duration stimulations (2–5 days) or higher concentrations of LXs may be required to assess the therapeutic effect of these drugs on these specific highly abundant cytokines. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similarly, the sensitivity of this proteome profiler approach for detecting subtle changes in low-abundance cytokines released from plaque tissue may not be sufficient, and more accurate measurements using ELISA may be more reliable. Nevertheless, this screening strategy has identified several cytokines robustly responding to LXA4. Interestingly, GM-CSF antagonism is currently being evaluated in several inflammatory disorders (43). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Secreted levels of several additional cytokines, including CCL3/MIP1a, CCL5/RANTES, and MCP-1, all produced by various leukocyte subsets in response to inflammatory stimuli, were also reduced by LXA4 treatment. Thus, we demonstrate LXA4 as an independent and effective proresolving modulator in the human plaque microenvironment building on our findings in preclinical models of atherosclerosis.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">10</td>
<td class="data">Global trends in diabetes complications: a review of current evidence</td>
<td class="data">SUMMARY =&gt; DIABETES-RELATED COMPLICATIONS =&gt; XXXXXXXXXXXXXXXXXXXXXXXXXX 1. Chronic or acute diseases caused by persistent metabolic and haemodynamic disturbances in diabetes. 
2. Generally described as microvascular (kidney disease, retinopathy and neuropathy) and macrovascular (cardiovascular) complications, but may also include consequences of diabetes-specific treatments, such as hyper- or hypoglycaemia. 
3. Despite  wide spread international assessment of the growth of diabetes prevalence, quantification of the international burden of and variation in diabetes-related complications is lacking. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX WHAT ARE RECENT AND LONG-TERM TRENDS IN DIABETES-RELATED COMPLICATIONS GLOBALLY? =&gt; XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1. Rates of  (lower extremity amputation) LEAs, acute complications, CVD, all-cause mortality and CVD mortality among people with diabetes are generally declining.
2. Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD mortality and ‘emerging’ complications are fewer and, hence, conclusions are limited. 
3. In spite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with those without diabetes. 
4. Comparable data on trends in rates of diabetes complications, specifically from low- and middle-income countries, is lacking. Conclusions drawn are mainly limited to high-income countries in North America, Europe and the Asia-Pacific region and the global state of diabetes complications remains unknown. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">11</td>
<td class="data">Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial</td>
<td class="data">Although previous observational studies have reported associations of circulating BCAAs and AAAs with adverse outcomes in healthy people, the present report contrasts for the
first time the associations of multiple circulating amino acids with the major vascular complications of diabetes. Rather than one (or more) amino acids being a consistent signal for adverse outcomes of any kind, we report that their associations with risk of macrovascular events, microvascular events and allcause mortality are strikingly different from each other. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A key finding is the inverse association of tyrosine with risk of microvascular events, independent of eGFR and urinary ACR. Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The association of high circulating concentrations of BCAAs and AAAs with obesity has been known since the 1960s [29] and has been proposed to be at least partially mediated by insulin resistance. Insulin is thought to be a regulator of branched chain  α-keto acid dehydrogenase complex [30]. Insulin resistance may hence suppress BCAA catabolism, as suggested by associations noted in observational epidemiology studies [31–33]. The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX There is also the possibility that amino acids themselves (particularly BCAAs) may affect metabolism by suppressing postprandial glucose levels [36]. Increased protein turnover in people with central obesity may result in higher circulating levels of amino acids [37] and might therefore cause elevations in amino acids in people who are overweight and have type 2 diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX There are hence a variety of potential mechanisms related to type 2 diabetes pathologies that might influence circulating amino acids in individuals with type 2 diabetes. Given this background, and prior findings in general populations of associations of specific amino acids with CVD [9–12], we wished to examine whether amino acid levels associated with adverse outcomes in individuals with type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the ADVANCE study, the BCAAs leucine, valine and isoleucine showed no association with macrovascular events, but low levels of leucine and valine were associated with increased all-cause mortality. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, the positive, albeit not independently predictive, association of phenylalanine with CVD and all-cause mortality we observed is broadly in line with other published data. There are limited intervention studies investigating the effect of amino acid supplements on health outcomes, with most research coming from short-term trials examining surrogate health markers in the sports science area [38]. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our study provides observations that are the basis for testable hypotheses investigating the effect of genetic variants, which are instrumental variables for circulating amino acids, on health outcomes [39, 40]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The inverse association of tyrosine with risk of microvascular events is perhaps the most intriguing individual finding from this study. Tyrosine itself was positively associated with baseline eGFR and inversely associated with baseline HbA1c and urinary ACR. Impaired conversion of phenylalanine to tyrosine has been reported in renal disease [41, 42]. Low tyrosine levels might therefore simply reflect impaired kidney function, which itself predicts future microvascular events. Tyrosine is also linked to catecholamine synthesis, which, also speculatively, might be relevant to our findings [43]. That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   CONCLUSIONS =&gt; In conclusion, we report distinct associations of different amino acids with risk of major adverse endpoints in individuals with type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">12</td>
<td class="data">Ethnic differences in infectious burden and the association with metabolic risk factors for cardiovascular disease: a cross-sectional analysis</td>
<td class="data">SUMMARY OF KEY FINDINGS =&gt; We found a higher IB among the 18 to 70-year old participants of Turkish and Moroccan origin in our study than among those of Dutch origin. This increased IB was significantly associated with a higher odds of diabetes, but the association was not as clear for elevated cholesterol and hypertension. In line with this finding, IB attenuated the ethnic disparities in diabetes. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DISCUSSION OF KEY FINDINGS =&gt; As expected, the Turkish and Moroccans had a higher IB than the Dutch. This was in line with previous reports signaling a higher prevalence of individual infections in these groups than the Dutch [26, 27]. The findings are also in line with the ethnic differences in IB reported in two studies from the US [23, 24]. In both studies, the IB was lower among the largely European origin population than among the other ethnic groups. As the prevalence of several infections was also found to be higher among other populations originating from low income countries living in the Netherlands, such as the Surinamese, Antilleans and Egyptians [26, 27, 36], a higher IB may also be expected in these groups. The finding that ethnic minorities have a higher IB than the general Dutch population is likely related to background prevalence in the country of origin, in combination with increased early life exposure before migration, or exposure during travel to their region of origin post migration. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Both Turkey and Morocco are countries with an increased background prevalence of, for instance, HAV and HBV compared to the Netherlands, and have been reported to have lesser hygienic circumstances [37]. Differences in IB may also be partly explained by increased susceptibility related to a lower socioeconomic position of ethnic minority groups or by differences in proportion vaccinated for HBV [23]. Poor circumstances may subject populations to social stress, which can down regulate the immunity, thus making these groups more susceptible to infections [38]. Additionally, the transmission dynamics may also be important. The historically high infection rates among ethnic minorities may partly remain due to the fact that minority populations live and work together, even as their socioeconomic positions change [23]. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The consistently positive association of IB with prevalent diabetes and the non-significantly positive associations with elevated cholesterol and hypertension in our population support a possible association between IB and these metabolic risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous studies have been inconsistent. For example, several studies reported positive associations with diabetes and its clinical markers [18, 19], elevated cholesterol [20, 21] and hypertension [19, 22] while others reported no association of IB with these factors [39, 40]. The differences between other studies and ours may be due to several reasons. The differences may simply reflect differences between the populations studied. Previous studies often did not included ethnic minority groups or did not adjust for ethnic differences in the analyses, despite known ethnic differences in infections and in metabolic risk factors [3–5]. Another possible explanation might be the lack of a consistent IB definition. Different studies have, for various reasons, used different combinations of chronic or past infections to define the IB.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In our study, for instance, we were unable to include several infections (e.g. C. pneumoniae, cytomegalovirus and Epstein-Barr virus were not measured) that have been associated with metabolic risk, and included by others in their definition of IB. On the other hand, we included data on HAV, HBV and HCV, which some but not all of these other studies included. The inconsistency across studies may also reflect the lack of insight into the exact mechanisms of risk and indicates the importance of further work to determine which infections or combinations of infections associate most strongly with metabolic risk. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Consistent with the lack of ethnic specific data on the association of IB with metabolic risk, there is also a lack of data on the possible contribution of IB to ethnic disparities in diabetes, elevated cholesterol and hypertension. Our findings suggest that IB may contribute to differences in, particularly, diabetes between the ethnic groups. If confirmed in larger studies among multiethnic populations, the potential implication is that reducing the burden of infections or timely initiation of treatment directed at diminishing or reversing its effects might contribute to reducing disparities between ethnic groups.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The mechanisms by which IB works (e.g. epigenetic effects or inflammatory processes) should then be studied, as well as specific patterns of infections, currency and chronicity of infections and the association of these with incidence of metabolic risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Unfortunately, the power of our study and availability of specific data limited a preliminary exploration of such specific patterns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In conclusion, our study showed that Turkish and Moroccan adults in Amsterdam have a higher IB than Dutch adults and that a higher IB was associated with differences in metabolic risk factors, in particular diabetes. Due to the cross-sectional nature of the study, we cannot draw any conclusions with regards to the time sequences of cause and effect. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">13</td>
<td class="data">Could Ceramides Become the New Cholesterol?</td>
<td class="data">While it is premature to equate the nascent studies relating ceramides to diabetes and heart disease with the exhaustive body of literature surrounding cholesterol, a foundation for such a comparison is beginning to emerge. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX One wonders whether ceramides are currently in the same position that cholesterol was in the 1980s. Will serum ceramides show the same prognostic utility as LDL cholesterol in large epidemiological studies? XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Will mutations in genes encoding ceramide modifying enzymes prove relevant to diabetes and heart disease?  XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Will ceramide synthesis inhibitors prove to be as efficacious in humans as they are in rodents? XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Regardless of what one thinks of this comparison or the likely answers to these questions, human beings are starting to monitor ceramide levels and are seeking answers about the ramifications of an altered ceramide profile.  XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">14</td>
<td class="data">A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: The EPIC-InterAct case-cohort study</td>
<td class="data">We evaluated fatty acid profiles among adults in 8 European countries and derived a FA-pattern score that represents a combination of both essential and non-essential fatty acids and that is characterised by high relative concentrations of linoleic acid (18:2n-6), stearic acid (18:0), odd-chain SFAs, and VLSFAs (&gt;=20 carbons), and by low relative concentrations of γ-linolenic acid (18:3n-6), monounsaturated fatty acids (MUFAs), and long-chain SFAs (14:0 and 16:0). The unique combination was associated with dietary, metabolic, and genetic factors, and prospectively associated with a lower incidence of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Comparing the top fifth to the bottom fifth of the FA-pattern score, T2D incidence was lower by approximately 60%. This robust association with incident T2D was independent of established risk factors and also any single fatty acids or fatty acid subclasses. These findings support the hypothesis that a combination of multiple fatty acids is an important marker for the development of T2D above and beyond the roles of single types of fatty acids. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The combination of essential and non-essential fatty acids is of strong interest for further clinical or population-based investigations to predict
T2D risk, identify interventional agents for T2D prevention, and better understand the aetiology of T2D. The combination of fatty acids contributing to the identified FA-pattern score fits with known mechanisms involving the de novo lipogenesis (DNL) pathway. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In DNL, fatty acids including 14:0, 16:0, 16:1n-7, and 18:1n-9 are synthesised endogenously, where stearoyl-CoA desaturase (SCD) converts 16:0 to 16:1n-7 as a rate-limiting step of fatty acid synthesis. The inverse correlation of 18:2n-6 with these fatty acids may reflect its role as a ligand of peroxisome proliferator-activated receptor α (PPARα) [2,5]. PPARα down-regulates SCD and ELOVL (elongation of very-long-chain fatty acid) enzymes, explaining the observed inverse correlation of 18:2n-6 with MUFAs, 16:0, 18:3n-6, and other n-6 PUFAs [2]. An exception of PPARα&apos;s action is activation of ELOVL3, which leads to synthesis of VLSFAs in the adipose tissue [35] and supports the observed associations between 18:2n-6, 18:0, and VLSFAs. While our findings are in line with the benefit of dietary PUFAs (predominantly 18:2n-6), other major PUFAs (e.g., omega-3 PUFA) contributed little to the primary fatty acid combination. This could reflect their diverse roles in eicosanoid pathways and pro- and anti-inflammatory pathways, and their associations with dietary intakes (e.g., fish) independent of DNL-driving dietary factors [5]. These suggested mechanisms are linked to the development of T2D. Activation of PPARα suppresses hepatic DNL and pro-inflammatory pathways that lead to insulin resistance, dyslipidaemia, and fatty liver [2,5,36]. In an experimental setting, for example, PPARα knock-out mice developed fatty liver exhibiting overt hepatic lipogenesis [37]. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Main products of DNL include 16:0 and diacylglycerols that cause a pro-inflammatory response, endoplasmic reticulum stress, and insulin resistance [1,38]. Thus, our analysis yielded a combination of multiple fatty acids that may represent biological pathways related to insulin resistance, inflammatory responses, and T2D risk. This was confirmed with the observed associations of FA-pattern score with metabolic risk factors in an expected direction and the association of FA-pattern score with genetic predisposition to insulin resistance. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Associations of gene variants with fatty acids and with incident T2D cannot be confounded by long-term lifestyle characteristics. Therefore, the specific gene variants, the identified combination of fatty acids, and the risk of T2D are likely to be on the same causal pathway, warranting future research to elucidate how insulin resistance specifically alters fatty acid profiles or vice versa. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our analysis and prior studies derived a similar combination of fatty acids [12-15], but no previous studies to our knowledge evaluated T2D incidence as an outcome. Past studies used different methods and examined varied numbers of fatty acids (10 to 42) of phospholipids [15], cholesteryl esters [12,15], plasma [13], or adipose tissue [14]. Despite the differences, all of the studies reported a combination of fatty acids partly driven by higher levels of 18:2n6 with lower 16:0, which could reflect activity of DNL [39]. These combinations were found to be associated with lower blood pressure, greater endothelial function, less weight gain over time, or lower risk of metabolic syndrome [12-14]. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, an association with ischaemic heart disease or stroke was not significant [15]. The inconsistency depending on outcome is predictable as DNL could promote insulin resistance, but suppress atherosclerosis [36]. Statins and other lipid-lowering drugs also alter fatty acid profiles [10] and have divergent effects on heart disease and T2D [40]. Thus, a fatty acid pattern can be a future focus of investigations of cardiometabolic diseases and related interventions. The association of the FA-pattern score with incident T2D was not fully explained by any single fatty acid, but was partly attenuated by adjustment for odd-chain SFAs and VLSFAs. These SFAs are associated with lower risk of cardiometabolic diseases [16,41,42], while their biological roles remains understudied. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX High phospholipid VLSFAs may reflect high activity of PPARα, which leads to VLSFA synthesis and less insulin resistance, apoptotic cell death, and
pancreatic dysfunction [41,43]. Blood odd-chain SFAs may partly reflect dairy consumption [3,44], gut microbiota [45], or endogenous synthesis through α-oxidation [46], and thus any correlates to those factors could explain our findings. Evidence for these mechanisms and relationships with other fatty acids remains scarce and deserves further investigation. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Dietary correlates with the combination of fatty acids deserve discussion, as they were replicated in EPIC-InterAct and NHANES: alcohol and soft drinks as negative correlates, and coffee, fibre, and PUFAs as positive correlates. The finding for alcohol consumption is likely to reflect its lipogenic effect, a risk factor for liver cirrhosis and T2D [47]. Regarding coffee consumption, polyphenols may deactivate DNL [48] and lower triglyceride levels and T2D risk [49-51]. Increased PUFA intake (predominantly n-6 PUFAs) could increase insulin sensitivity as well as lower DNL [2,5,52]. Our findings for soft drinks and fibre may also reflect their glycaemic and anti-glycaemic effects, respectively, as a high glycaemic effect leads to insulin secretion and DNL [2,53].   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In conclusion, we identified a combination of plasma phospholipid fatty acids characterised by high relative concentrations of 18:2n-6, VLSFAs, and odd-chain SFAs and low relative concentrations of long-chain SFAs and MUFAs, some of which are synthesised endogenously. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This particular profile was associated with a 3-fold lower relative risk of incident T2D in European populations after adjustment for confounding. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX While both genes and diet were linked to the FA-pattern score, association of the FA-pattern score with T2D was independent of established
risk factors for T2D and not driven by individual fatty acids. These findings highlight that multiple fatty acids are jointly related to the development of T2D.   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">15</td>
<td class="data">Obesity and inflammation: the linking mechanism and the complications</td>
<td class="data">Sustained inflammation is considered a strong risk factor for developing many diseases including CVDs, metabolic syndrome, diabetes, and cancer. As a risk factor, obesity predisposes to a pro-inflammatory state via increased inflammatory mediators IL-6 and TNF-α, and reduced levels of adiponectin, which has totally anti-inflammatory function. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX According to Badawi et al. [137], TNF-α is overexpressed in the overweight state, while IL-6 is linked more to the obese state that influences the liver to synthesize and secrete CRP, which is a feature of systemic inflammation. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This state is associated with reduced levels of adiponectin, which is important in improving insulin sensitivity, reducing metabolic abnormalities, and adjusting the energy expenditure. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, the inflammatory state followed by vascular and endothelial dysfunction is characterized by decreased nitric oxide and elevated reactive oxygen species leading to oxidative stress. Both statuses of oxidative stress and inflammation initiate atherosclerosis, hypertension, alteration of metabolic markers, and thus major adverse cardiovascular events. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">16</td>
<td class="data">Diabetic Kidney Disease: Challenges, Progress, and Possibilities</td>
<td class="data">TREATMENT OF DKD =&gt; Prevention of diabetic complications, particularly DKD, by long-term intensive glycemic control from early in the course of diabetes is well established for DM1 and DM2 (19,22). However, intensive glucose control after onset of complications or in longstanding diabetes has not been shown to reduce risk of DKD progression or improve overall clinical outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Targeting low HbA1C (6%–6.9%) compared with standard therapy in this population did not reduce risk of cardiovascular (CV) or microvascular complications but increased the risk of severe hypoglycemia (54–56). Furthermore, an analysis of patients with DM2 and early-stage CKD showed 30% and 40% higher risks for all cause mortality and CV mortality, respectively, with intensive glycemic control compared with standard therapy (57). The finding that intensive glycemic control incurs great risk of hypoglycemia and does not benefit the risk of CVD or all-cause mortality has been sustained over the long term (8–10 years). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A small benefit of intensive glycemic control on the risk of ESRD was observed, but the absolute number of patients was minute (58). A stratified analysis showed that the greatest benefit of intensive glycemic control for preventing ESRD was seen in participants without kidney disease at study entry, further supporting the concept that intensive glycemic control initiated during early diabetes can prevent DKD (59). XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The American Diabetes Association recommends that targets for glycemia should be tailored to age, comorbidities, and life expectancy of individual patients. More stringent goals, such as HbA1C, 6.5%, may be reasonable for patients with shorter duration of diabetes, younger age, absence of complications, and a longer life expectancy. To the contrary, less stringent goals of HbA1C, 8% are recommended for patients with longstanding diabetes, older age, micro- and macrovascular complications, and limited life expectancy (51). Similarly, the National Kidney Foundation–Kidney Disease Outcomes Quality Initiative and the Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend a target HbA1c of about 7.0% to prevent or delay progression of the microvascular complications of diabetes. However, patients at risk for hypoglycemia, such as those with diabetes and CKD, should not be treated to an HbA1c target of &lt; 7.0% (53). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For management of hypertension, the Eighth Joint National Committee (JNC-8) recommended initiation of pharmacologic treatment at a systolic BP &gt;=140 mmHg or diastolic BP &gt;=90 mmHg, with treatment goals less than these levels. In the general hypertensive population, including those with diabetes, initial antihypertensive treatment may include a thiazide-type diuretic, a calcium channel blocker, an angiotensin-converting enzyme (ACE) inhibitor, or an angiotensin receptor blocker (ARB). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In black patients with diabetes, the JNC-8 recommends initial treatment with a thiazide diuretic or calcium channel blocker. The same BP targets are recommended for those with CKD irrespective of diabetes status.XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In patients who are diabetic with high levels of albuminuria, the medication regimen should include an ACE inhibitor or an ARB alone or in combination with medication from another drug class (60). The KDIGO guidelines recommend use of an ACE or an ARB and a BP goal &lt; 130/80 mmHg in all patients with CKD and albuminuria irrespective of diabetes status (52). There is unambiguous evidence that renin-angiotensin system blockade with either an ACE inhibitor or an ARB reduces the progression of DKD in patients with macroalbuminuria (61). XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, combination therapy (an ACE inhibitor and an ARB administered together) increases the risk of serious side effects, primarily hyperkalemia and AKI, and offers no clinical benefits (62,63). XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Following the liberalized JNC-8 recommendations, target BP goals have been challenged by results of the Systolic BP Intervention Trial (SPRINT). The SPRINT included 9361 non-diabetic participants with hypertension and high CV risk. Participants were randomized to either an intensive (&lt; 120 mmHg) or standard (&lt; 140 mmHg) systolic BP goal. The trial was terminated early after a median of 3.26 years, because rates of the primary outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from CV causes) and all-cause mortality were reduced by 25% and 27%, respectively, in the intensively treated group compared with the standard regimen group. These results held across pre-specified subgroups defined according to CKD stage, age &gt; 75 years old, sex, race, previous CVD, and baseline levels of systolic BP (64,65). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to the SPRINT, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial, which included 4733 patients with diabetes at high risk for CV events, showed that achieving the same systolic BP targets (&lt; 120 versus  &lt; 140 mmHg) did not have a statistically significant effect on the risk of non-fatal myocardial infarction, non-fatal stroke, death from CV cause, or death from any causes (66). One of the possible explanations for this incongruent finding is that the ACCORD Trial was underpowered to show between-group differences, because CV morbidity and mortality occurred at substantially lower rates than predicted. However, in the SPRINT participants who had CKD at study entry, intensive BP treatment did not reduce incidence of ESRD, cause a 50% decline in eGFR, or cause &gt;=30% decline in eGFR to a value of &lt; 60 ml/min per 1.73 m2. Furthermore, hospitalizations or emergency room visits for AKI occurred more frequently in the intensive treatment group than the standard regimen group (4.4% versus 2.6%; hazard ratio, 1.71) (64,67). Similarly, the ACCORD Trial detected a signal suggestive of a possible negative effect of intensive BP control on kidney function. Even among participants who had normal kidney function at baseline, instances of eGFR=&lt;30 ml/min per 1.73 m2 were almost doubled in the intensive treatment group (99 in the intensive treatment group versus 52 in the standard treatment group; P &lt;0.001) (66). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX NOVEL THERAPIES AND APPROACHES =&gt;  Despite current approaches to management of diabetes and hypertension and use of ACE inhibitors and ARB,
there is still large residual risk in DKD. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Novel agents targeting mechanisms, such as glomerular hyperfiltration, inflammation, and fibrosis, have been a major focus for development of new treatments. Agents that have shown promise include ruboxistaurin, a protein kinase C-b inhibitor (68); baricitinib, a selective Janus kinase 1 and Janus kinase 2 inhibitor (69); pentoxifylline, an anti-inflammatory and antifibrotic agent (70); atrasentan, a selective endothelin A receptor antagonist (71,72); and finerenone, a highly selective nonsteroidal mineralocorticoid receptor antagonist (Table 4) (73). However, thus far, there are no available phase 3 clinical trial data for these agents, and none are approved for use in DKD. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Since the year 2008, the US Food and Drug Administration has mandated that new antihyperglycemic therapies seeking approval for the treatment of DM2 must show CV safety. Three agents within the glucagon-like peptide-1 receptor agonist class of medications, lixisenatide, liraglutide, and semaglutide, currently have CV outcome trial data available. The Evaluation of Lixisenatide in Acute Coronary Syndrome Trial showed that the addition of lixisenatide to standard care did not significantly alter the rate of major CV events (74). In contrast, in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Study and the Trial to Evaluate Cardiovascular and Other Long-Term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), fewer participants reached the primary composite CV end point in the liraglutide and semaglutide groups compared with those receiving placebo (hazard ratio, 0.87; P = 0.01 for superiority and hazard ratio, 0.74; P &lt; 0.001 for non-inferiority, respectively) (75,76). Notably, similar benefits on CV outcomes were observed in the LEADER Study and the SUSTAIN-6 subsets with moderate to severe CKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Studies in patients with DKD have additionally shown that liraglutide lowered albuminuria levels in patients with normal kidney function or early stage CKD and showed improved glycemic control in CKD stage 3 (75). Recently released data from clinical trials of semaglutide and dulaglutide consistently show reduced risk of albuminuria onset and progression (75,76). The consistency of these data across glucagon-like peptide-1 receptor agonists persuasively suggests a class effect of protection from DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The mechanisms of action may be multifactorial and include glycemic control, weight control, and direct effects on the kidney. In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients, an sodium-glucose cotransporter 2 inhibitor, empaglifozin, also showed significantly lowered rates of death from CVD causes (38% relative risk reduction), hospitalization for heart failure (35% relative risk reduction), and death from any cause (32% relative risk reduction) compared with placebo (77,78). Analysis of pre-specified secondary outcomes showed that empaglifozin also slowed progression of DKD and lowered rates of clinically relevant kidney outcomes among patients with CKD stages 2–4 (78) (Table 5).  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX POPULATION-BASED APPROACHES =&gt; Success of this strategy has been shown by recently available data from the Centers for Disease Control. A 54% decrease in diabetes-related kidney failure occurred between the years 1996 and 2013 among American Indians, a group with a historically high prevalence of diabetes and DKD. Interventions leading to this change included systematic implementation of guidelines for treatment of hypertension and diabetes, regular albuminuria testing, use of ACE inhibitors and ARBs, services to support nutrition, physical activity, and diabetes education (79). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSION =&gt; Since the discovery of insulin in the 1920s, research has made significant strides toward understanding and improving the clinical management of diabetes. Although these advances have meaningfully improved outcomes for
diabetes complications, such as CVD, these improvements have not translated nearly as well to DKD or ESRD (80). XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In response, the International Society of Nephrology has convened a Global Kidney Health Initiative to call attention to kidney diseases overall. Key collaborative stakeholders in the quest to fight DKD should include patients, health care providers and payers, advocacy groups, scientists, and governmental agencies. Advocacy and a call to action are essential to effective dissemination and implementation of current best practices. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Using public health and population approaches in clinical practice and promoting meaningful and strategic research will be key to improving health outcomes for people with diabetes and DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">17</td>
<td class="data">Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers</td>
<td class="data">Using a targeted metabolomics approach across three cohorts, we identified arginine, LPC 17:0 and LPC 18:2 as metabolite biomarkers for incident MI. Adding arginine, LPC 17:0 and LPC 18:2 to the FRS significantly increased the predictive value in fasting cohorts and in a meta-analysis of the three cohorts. These metabolite biomarkers were independent of conventional risk factors for MI, but strongly attenuated the hsCRP–MI associations indicating a potential role in systemic inflammation. Although this is the first time that these three metabolites in combination have been suggested as biomarkers for incident MI, each has been linked to CVD. (31–35). XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ARGININE =&gt; An SD increase in serum arginine concentrations was associated with a 26% higher risk of incident MI risk in the meta-analysis. Ornithine, a product of splitting urea from arginine, is associated with CHD. (36) A possible mechanism linking arginine and inflammation is production of oxygen radicals (O2−) and peroxynitrite. Arginine is metabolised to NO via the NO synthases NOS3 and NOS2 in vascular cells. (37) In the presence of high concentrations of O2−, NO reacts with O2− to generate peroxynitrite, reducing the bioavailability of NO and contributing to inflammatory processes. (38, 39) Additionally, peroxynitrite and O2− trigger the uncoupling of NO synthases, shifting the production of NO to O2−, (40) creating a feedback loop (figure 3). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX LYSOPHOSPHATIDYLCHOLINES =&gt; LPCs are associated with lipid metabolism, inflammation and MI. (31–34, 41, 42) In our study, participants with higher serum LPC 17:0 and LPC 18:2 concentrations had a lower risk of MI. LPCs also have a negative association with a combined CVD outcome of MI, ischaemic stroke and sudden cardiac death, (14) further supporting our findings, and LPC 18:2 is associated with CHD. (16) LPCs are associated with inflammatory processes via a variety of mechanisms (figure 3). LPCs can increase expression of NOS3, which is involved in NO synthesis. (31) LPCs can also drive production of antioxidant enzymes, for example, SOD3, which reduce superoxide anion concentrations (figure 3). (32) As a consequence, lower LPC concentrations may increase oxidative stress and promote inflammation as indicated by the negative association with hsCRP. Finally, LPCs increase the synthesis of prostaglandin I2 resulting in improved vasodilation. (34, 41) Thus, lower LPC concentrations may contribute to endothelial dysfunction, increasing the risk for MI. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX HIGH-SENSITIVITY C REACTIVE PROTEIN =&gt; hsCRP is a measure of systemic inflammation. Our three metabolite biomarkers explained 10% of the variation in hsCRP concentrations and attenuated the hsCRP–MI association coefficient by 34%–74%, making it no longer significant (see online supplementary table S6). Therefore, inflammation likely represents a pathway through which our novel biomarkers are associated with MI. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX       MI RISK PREDICTION AND PREVIOUS CVD STUDIES =&gt; Metabolomics can potentially reveal causal biomarkers with strong predictive value for CVD, (9) and baseline metabolomics profiles are associated with risk of death or incident MI. (11) Recently, there have been several metabolomic studies using general population-based cohorts. (14–16, 36) Stegemann et al used a shotgun lipidomics approach to identify lipid species associated with incident CVD. (14) Würtz et al used a Nuclear magnetic resonance (NMR)-based approach to identify CVD-associated metabolites and calculate a risk score for CVD. (15) Vaarhorst et al also used an NMR-based approach and identified metabolites associated with incident CHD; however, their score did not significantly increase CHD risk prediction. (36) Ganna et al used an LC-MS / MS-based lipidomics approach and associated LPC 18:2 with CHD. (16) Covering 140 metabolites, our MS approach is more comprehensive than that taken by Stegemann et al (135 metabolites), Vaarhorst et al (100 metabolites) or Würtz et al (68 metabolites), and with 266 incident MI events, our study is the largest by the number of MI events. Additionally, while previous studies assessed a combined cardiovascular endpoint, (11, 14, 36) we exclusively analysed incident MI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  CONCLUSION =&gt; We identified three metabolite biomarkers associated with incident MI which improved MI prediction when added to the FRS. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We replicated this MI prediction improvement in independent fasting samples. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These three metabolites were associated with hsCRP and attenuated the hsCRP–MI association while being independent of other traditional CVD risk factors, indicating a potential link to systemic inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">18</td>
<td class="data">The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease</td>
<td class="data">ADDITIONAL CONSIDERATIONS FOR THE USE OF METABOLOMICS IN THE DIAGNOSIS AND PROGNOSIS OF CVD =&gt; Although the majority of this review has focused on how blood-based metabolomics can aid in the diagnosis and prognosis of various CVDs, patients with CVD often also have associated comorbidities, such as kidney disease and hepatic steatosis, as well as obesity and/or T2D (8,17). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In fact, obesity and/or T2D may add extreme complexity to the understanding of the metabolomic profile, because these conditions often result in significant pathology and perturbed metabolism in other peripheral tissues (e.g., skeletal muscle, liver, adipose tissue, among others), and these peripheral tissues also contribute to the circulating metabolomic profile measured in patients with CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Indeed, systemic insulin resistance is a hallmark feature of obesity and T2D, and metabolomic profiling in obese and/or diabetic subjects often reveals increases in circulating lactate levels (74,75), which on the surface suggest increases in anaerobic glycolysis (Figure 1). However, increases in anaerobic glycolysis are not consistent with systemic insulin resistance, which impairs glucose metabolism in numerous tissues, including skeletal muscle. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Conversely, proteomic studies have observed increases in the expression of glycolytic enzymes in vastus lateralis biopsies from obese and T2D patients (76). Furthermore, the source of elevated lactate in the circulation is difficult to ascertain, and can arise from other sources in addition to skeletal muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Because adipose tissue dysfunction in obesity is often associated with tissue hypoxia (77), increased anaerobic glycolysis in the expanded adipose depots of obese individuals may also contribute to this elevation in circulating lactate. As circulating free fatty acids and triacylglycerols are markedly increased during obesity/T2D, fatty acid supply, uptake, and metabolism are frequently increased in peripheral tissues, such as the skeletal muscle and heart. Metabolomic profiling to assess alterations in fatty acid metabolism in obese and/or diabetic subjects has revealed increases in numerous circulating acylcarnitine species (52), whereas other studies have reported no differences (78). XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It has been suggested that a very large portion of the circulating acylcarnitine pool arises from skeletal muscle-mediated export, and muscle biopsies in obese humans also demonstrate increases in M-C and L-C acylcarnitines compared with lean controls (79). Thus, assessment of acylcarnitine profiles via blood-based metabolomics supports increases in both skeletal muscle and myocardial fatty acid oxidation rates (see the section Metabolomics and CVD in Obesity and Diabetes), although additional investigation is required to determine the contributions individual organs make to the circulating acylcarnitine profile.  XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Circulating ketone bodies (e.g., b-hydroxybutyrate and acetoacetate) are frequently elevated in obese and/or T2D patients (80), and elevations in circulating ketone bodies predict worsening of hyperglycemia in men with or without newly diagnosed T2D (81). Changes in circulating b-hydroxybutyryl-carnitine may reflect changes in peripheral tissue ketone body oxidation because b-hydroxybutyryl-carnitine is a mitochondrial intermediate derived directly from b-hydroxybutyryl-CoA (30). Of interest, recent findings from the EMPA-REG OUTCOME trial have observed that treatment with the sodiumglucose cotransporter 2 inhibitor, empagliflozin, markedly lowers cardiovascular risk in T2D patients, including a 35% reduction in hospitalization for HF (82). As these exciting findings were associated with a significant increase in circulating b-hydroxybutyrate levels, it has been suggested that empagliflozin reduces cardiovascular risk by increasing ketone body uptake and oxidation in the heart (83). This is consistent with increased ketone body oxidation being a potential beneficial and adaptive mechanism in the failing heart (see the section Metabolomics and HF), and highlights the need to understand the significance of blood-based metabolomic profiles revealing perturbations in ketone body metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Numerous studies have illustrated a tight correlation between circulating BCAA levels and risk for insulin resistance/T2D (2,75). Since these initial observations, several investigators have utilized novel metabolomic profiling techniques to implicate BCAAs in obesity and insulin resistance (2,17), with BCAAs and aromatic amino acids emerging as predictors of future T2D. Intriguingly, generation of an amino acid score on the basis of 3 of these amino acids (isoleucine, phenylalanine, and tyrosine) was found to significantly predict incident T2D (84). In light of findings suggesting impaired myocardial BCAA/BCKA metabolism in HF (63), it will be important to understand how the circulating BCAA profile in obesity reflects deranged systemic and myocardial metabolism. Taken together, although blood-based metabolomics is proving to be a powerful tool that can assist in the diagnosis and prognosis of CVD, in the context of obesity and/or T2D, caution must be applied in how we infer the associated peripheral metabolic perturbations. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX FINAL SUMMARY AND IMPLICATIONS =&gt; Metabolomic profiling technologies have significantly evolved to a point where high-resolution and high-throughput assessment of thousands of metabolites within a biological sample can be performed with relative ease. Due to the expansive biochemical diversity of metabolites within the human metabolome, several complementary platforms and techniques are necessary for comprehensive metabolic characterization. These techniques, MS and NMR coupled with LC or gas chromatography, are exquisitely sensitive, generating the metabolic fingerprint of a biological sample that not only reflects the condition of interest, but also diet, drug effects, sex, and other comorbidities and exposures. Thus, human metabolomic studies are consequently prone to clinical confounding factors that may lead to spurious diagnoses / conclusions. Yet the application of metabolomic profiling to several large population-based epidemiological cohorts has allowed for robust statistical adjustment for potential confounders, and has resulted in externally reproducible findings. In addition, metabolomics has been applied in smaller
studies of unique clinical scenarios that allow for serial sampling before and after a controlled biological perturbation (e.g., exercise testing, planned MI, drug administration, and so on). Such paired experiments allow subjects to serve as their own controls, mitigating the risk of confounding factors. In addition, emerging investigational techniques are integrating metabolomics with other “omics” platforms in order to gain insight into pathophysiological interactions of metabolites, proteins, genes, and disease states. Furthermore, the state-of-the-art metabolomic technologies now available provide us with a snapshot of the metabolic fingerprints of individual patients, which can serve as diagnostic and/or prognostic tools that can be used to identify impairments in systemic or myocardial metabolism occurring during the development and worsening of CVD, as well as identifying the types and timing of specific interventions / therapies. Thus, metabolomics is a powerful technology that is transforming our ability to predict, detect, and understand a myriad of cardiometabolic disease states, and to monitor the effectiveness of therapeutic interventions. In doing so, metabolomics continues to advance our societal objective of personalizing the practice of medicine. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">19</td>
<td class="data">Worldwide Exposures to Cardiovascular Risk Factors and Associated Health Effects: Current Knowledge and Data Gaps</td>
<td class="data">Following the expansion of, and advances in, epidemiological research on the behavioral, dietary, environmental, and physiological causes of CVDs, the number of CVD risk factors in global (comparative risk assessment) CRA analyses has increased substantially, from a handful in 1990 to tens in recent analyses. The CRA analyses have attributed hundreds of thousands or millions of CVD deaths to the aforementioned risk factors. These numbers have in turn helped draw attention to important global or regional public health issues. The above-mentioned limitations and gaps in data on risk factor exposure and effect sizes should not overshadow the tremendous advances in understanding the causes of CVDs, and in measuring their levels in worldwide populations, because the first cohort studies were done over 6 decades ago. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Rather, they should motivate future efforts in collecting new data and reanalyzing existing data that can improve our knowledge of the worldwide CVD effects of risk factors, as outlined in Table 2. Even with these uncertainties, a number of policies and interventions identified in Table 2, if successfully implemented, are likely to reduce the worldwide burden of CVDs through primordial prevention at the population level. (176) Together with equitable access to high-quality health care for CVD prevention and treatment, these actions can help replicate the successes of high-income countries in reducing CVD events and deaths, and to reduce global inequalities in CVD burden. (3–5, 160, 176) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, we note that CVDs and most of their risk factors are strongly inversely associated with individual and community socioeconomic status, as summarized in previous reviews. (19, 160) The higher CVD incidence and mortality in the poor is, at least in part, mediated by less favorable risk factor levels and more limited and lower quality health care for prevention and treatment, (18, 160, 161) although independent pathways may also exist. Therefore all CVD prevention policies, and scientific analyses that inform them, should take into account their impacts on CVDs on the poor and on inequalities. (160)XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">20</td>
<td class="data">Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation</td>
<td class="data">Recent data highlighted sphingolipids as potential therapeutic targets in the atherosclerotic process. Sphingolipids are increased in human plaque tissue, and in vitro studies have shown possible effects of these lipids on the atherosclerotic process. However, no studies have studied their association to atherosclerotic plaque phenotype and their potential role as pro-inflammatory mediators in human atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS AND PLAQUES ASSOCIATED WITH SYMPTOMS =&gt; All 6 analyzed sphingolipids were increased in plaque tissue associated with symptoms, suggesting a possible relationship between these sphingolipids and plaque vulnerability. Glucosylceramide and lactosylceramide have in previous studies been shown to be increased in human atherosclerotic plaques, (3, 4) but differences between symptomatic and asymptomatic plaques have not previously been studied. However, the increased levels of sphingolipids observed in the symptomatic plaques do not tell us whether sphingolipids contribute to plaque instability or whether they result from increased inflammatory activity after the event of a plaque rupture. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS AND ATHEROSCLEROTIC PLAQUE INFLAMMATION =&gt; To assess plaque inflammation, the content of macrophages in plaques was determined histologically, and plaque content of cytokines was measured in plaque homogenates. Glucosylceramide, lactosylceramide, and dihydroceramide correlated with plaque content of macrophages. The positive association between glucosylceramide and macrophages may be explained by the fact that glucosylceramide levels are high in human plaque monocytes as shown by Chatterjee et al. (4) Accordingly, it has been shown that ox-LDL increases macrophage lactosylceramide synthesis, (15) but the association with lactosyl-ceramide and macrophages may also be the effect of enhanced macrophage migration because of lactosylceramide dependent induction of adhesion molecule expression on monocytes and endothelial cells. (13) Because histological measurement of macrophages on cryosections from the 1-mm thick fragments of the most stenotic region of a plaque is a blunt, limited way to study inflammation, we also evaluated cytokine levels in the majority of the plaque tissue. This provided a more complete characterization of the inflammatory activity within the plaque and showed that all analyzed sphingolipids, with the exception of S1P, correlated with several proinflammatory cytokines and in general most strongly to MCP-1, MIP-1β, and IL-6. Yet, S1P correlated positively with the proinflammatory cytokines RANTES and TNF-α. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS, NEUTRAL LIPIDS AND OX-LDL =&gt; To further evaluate the association of sphingolipids and plaque instability, the content of neutral lipids (oil red O) and ox-LDL were measured histologically. The vulnerable plaque is known to be rich in ox-LDL. (16) Ox-LDL increases matrix metalloproteinase-2 activity, an enzyme that is highly present in plaques and activates neutral sphingomyelinase in human aortic smooth muscle cells, which in turn activates the sphingomyelin / ceramide pathway resulting in enhanced sphingomyelin hydrolysis into ceramide and eventually S1P. (17) However, in this study, ceramide correlated with plaque content of ox-LDL, LDL, and sphingomyelin (r=0.836; P&lt;0.001). Additional analyses to evaluate plaque A-SMase were performed, but beyond the location of the enzyme, we were not able to distinguish differences in enzyme activity. Studies by Chatterjee et al (18, 19) have also shown that the biosynthesis of lactosyl-ceramide from glucosylceramide is regulated by LDL and ox-LDL levels. Higher levels of LDL suppress lactosylceramide synthase, an enzyme promoting synthesis of more complex glycosphingolipids from glucosylceramide (Figure 1), which thereby inhibits synthesis of lactosylceramide from glucosylceramide. Both lactosylceramide and glucosylceramide correlated with plaque content of lipids in the present study. Despite not reaching significance (P=0.06), a tendency was found between plaque content of ox-LDL and lactosylceramide, fitting with the idea of ox-LDL promoting lactosylceramide formation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS AS POSSIBLE INDUCERS OF INFLAMMATION IN VITRO =&gt; To investigate whether the measured sphingolipids induced an inflammatory response in vitro, (human coronary artery smooth muscle cells) HCASMCs were incubated with the different sphingolipids in increasing concentrations. All 6 sphingolipids induced a significant release of IL-6 from HCASMCs in high concentration (10 μmol/L), consistent with the correlations found in plaque homogenates. Glucosylceramide, lactosylceramide, dihydroceramide, sphingomyelin, and S1P were also shown to induce IL-6 release already at concentrations of 1 μmol/L. Additional experiment also confirmed that glucosylceramide induced a significant release of MIP-1β, TNF-α, MCP-1, and RANTES from HCASMCs. Interestingly, glucosyl-ceramide induced the release of these cytokines even at relatively low concentrations when compared with the median plaque concentrations of glucosylceramide. Few studies have investigated the associations between ceramide, glycosphingolipids, and atherosclerotic plaque inflammation. However, some evidence supports the associations found in this study. Accordingly, the levels of MCP-1, a strong inducer of monocyte migration, has been shown to be increased in mouse models accumulating ceramide. (9) Furthermore, Bietrix et al (14) showed that inhibition of glucosylceramide synthase decreased TNF-α and MCP-1 mRNA expression. The hypothesis of glucosylceramide as an inducer of TNF-α and MCP-1 expression / release is supported by our findings. Glucosylceramide correlated with both TNF-α and MCP-1 in plaque homogenates and induced a release of these cytokines in vitro. Although sphingolipids were only shown to induce an inflammatory response in HCASMCs and not in human macrophages, this does not rule out their potential contribution to atherosclerotic plaque inflammation. According to the present ex vivo and in vitro findings, sphingolipids do seem to play an important role in atherosclerotic inflammation. As the (vascular smooth muscle cells) VSMCs are located in the media or in the cap near the endothelium and the arterial lumen, the release of cytokines from these cells would induce an inflammatory activated state in the endothelium and stimulate inflammatory cell migration. This suggests that sphingolipids may contribute to an early inflammatory response and attract inflammatory cells to the site of atherosclerotic plaque development rather than activating monocytes and macrophages within the atherosclerotic tissue. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX APOPTOSIS OF VSMCs IS INDUCED BY SPHINGOLIPIDS =&gt; VSMCs are important for maintaining plaque stability. (20) The loss of stabilizing VSMC is one of the important features of the vulnerable plaque leading to a thin protective cap and risk for developing a subsequent plaque rupture. (21–24) Whether ceramide and lactosylceramide can be considered as inducers of apoptosis is controversial. As mentioned, lactosylceramide has been shown to induce proliferation in human aortic smooth muscle cells; conversely, there is also evidence for lactosyl-ceramide and ceramide as mediators of SMase-induced apoptosis in human osteosarcoma cell lines and endothelial cells. (5–7) According to our results, ceramide and lactosylceramide were negatively associated with plaque content of VSMCs. These findings were further supported by the positive correlation found between ceramide, lactosyl-ceramide, and plaque levels of caspase-3. Although a tendency toward increased plaque levels of glucosylceramide and caspase-3 levels was found, the association did not reach statistical significance. To evaluate the effect on apoptosis, HCASMCs were incubated with the different sphingolipids in increasing concentrations. At concentrations of 1 and 10 μmol/L, glucosylceramide, lactosylceramide, and ceramide were shown to induce apoptosis, whereas only concentrations of 10 μmol/L induce cellular necrosis. The levels of sphingolipids needed for inducing apoptosis in vitro are generally higher than the median levels of sphingolipids in the plaque tissue. However, it is difficult to compare concentrations in plaque tissue and in cell culture medium. Considering the median levels of glucosylceramide, lactosylceramide, and ceramide (0.25, 0.12, and 0.11 μmol/g wet weight plaque, respectively) and the concentrations needed to induce cellular apoptosis and IL-6 release (1–10μmol/L), it cannot be excluded that the used concentrations are of biological relevance. Furthermore, knowing that the atherosclerotic plaque is a heterogeneous tissue, it is likely that the levels of sphingolipids will differ in different locations within the tissue, and local concentrations of sphingolipids may be several times higher than the median homogenate levels at some locations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX S1P DOES NOT ASSOCIATE WITH PLAQUE INFLAMMATION OR VULNERABILITY =&gt; In contrast to the other investigated sphingolipids, S1P has been suggested to have anti-atherogenic as opposed proatherogenic properties. (25) In plaque tissues, S1P did not correlate with either histological markers of plaque vulnerability or inflammation. When analyzing plaque cytokine levels, S1P was significantly correlated with TNF-α and RANTES. However, S1P failed to induce an inflammatory cytokine release from HCASMCs in vitro. Only at a high concentration (1 and 10 μmol/L), in comparison to median plaque levels (3.1×10−4 μmol/g), was an increase in IL-6 release detected, suggesting that the effect on IL-6 release is not biologically relevant in vivo. Interestingly, S1P was the only sphingolipid that was positively associated with the growth factor PDGF in the plaque tissue. PDGF stimulated VSMC growth and collagen production and is generally considered to contribute to a stable plaque phenotype. PDGF may also stimulate S1P production by activating sphingosine kinase leading to increased S1P levels. (26) S1P was unexpectedly found to correlate with caspase-3 levels. On the contrary, S1P did not induce HCASMC apoptosis in the in vitro experiments, not even at high concentrations. It has been suggested that an imbalance in ceramide / S1P levels could differentiate between cellular apoptosis and survival. (27) Considering the median ceramide / S1P ratio (109 / 0.31 nmol/g), this could be a possible explanation. However, it could be argued that this theory should show an inverse association rather than a positive association between S1P and caspase-3. Furthermore, ceramide and S1P levels correlated positively (r=0.321; P&lt;0.001), which may not support this theory although it does not exclude it. Taken together, the present findings suggest that S1P levels may be associated with cellular apoptosis but does not contribute to it. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX mRNA EXPRESSION OF SPHINGOLIPID PATHWAY ENZYMES =&gt; As the synthesis and degradation of sphingolipids are tightly regulated by a broad spectrum of enzymes, RNA sequencing was performed to investigate whether an increase in plaque levels of sphingolipids and glycosphingolipids could be explained by differential expression of genes coding for enzymes involved in relevant pathways. In the current analysis, no significant differences in the expression of these enzymes were observed. This does not rule out the role of these enzymes in plaque progression, as enzyme activity or localization could also be involved and remain to be evaluated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  CONCLUSIONS =&gt; In conclusion, this is the first study to demonstrate that glucosylceramide, lactosylceramide, ceramide, dihydroceramide, sphingomyelin, and S1P are increased in human atherosclerotic plaques associated with symptoms. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The current analysis also provides evidence that ceramide, lactosylceramide, and particularly glucosylceramide are not only associated with plaque inflammation and vascular smooth muscle apoptosis but also contribute to it. Our findings suggest an important role for sphingolipids in vulnerable plaque formation and that inhibiting specific targets in sphingolipid formation may, therefore, be a potential therapeutic target. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">21</td>
<td class="data">Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase</td>
<td class="data">Metabolomic profiling of statin use in longitudinal cohorts uncovered an intricate association pattern of circulating lipoprotein, fatty acid, and metabolite changes, which adds to our understanding of the LDL-C–independent effects of statins. Statin use was associated with pronounced lowering of numerous lipids and fatty acids consistent with the cardioprotective effects. By contrast, statin use did not markedly affect the circulating levels of recently identified biomarkers for cardiometabolic risk such as amino acids, glycolysis- and glycogenesis-related metabolites, or ketone bodies (5,6,21,31). The genetic proxy for HMGCR inhibition gave rise to a strikingly similar association pattern, providing unconfounded evidence that the observed metabolic changes arise as a consequence of the mechanism-based effect of statins (Central Illustration). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These insights into an extensively studied therapeutic agent illustrate how metabolomics, combined with genetic proxies mimicking pharmacological action, can elucidate the molecular effects of known targets, clarify treatment indication, and potentially be used to inform drug development (19,20,34). XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Inhibition of HMGCR by statins leads to upregulated expression of LDL receptors in the liver, which in turn increases the uptake of circulating LDL particles. Using lipoprotein subclass profiling, statin therapy also was shown to be associated with considerable lowering of IDL and very small VLDL particle concentrations, beyond the anticipated decrease in LDL particles. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These remnant lipoprotein particles carry 20% to 30% of circulating cholesterol; they are small enough to enter the arterial intima and, therefore, possess the potential to cause atherosclerosis (14). Because total triglyceride concentration is highly correlated with the amount of IDL and small VLDL particles and their cholesterol levels, the triglyceride measure may partly reflect the cardiovascular risk mediated by the atherogenic remnant particles (14,15). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Indeed, accumulating genetic evidence suggests that triglyceride levels reflect causal processes related to coronary heart disease (13–15); however, the likely underpinning mechanism is the remnant cholesterol carried in the IDL and VLDL particles (14,15,35). Detailed lipoprotein profiling demonstrated that statins are effective in lowering remnant cholesterol, whereas triglycerides are only modestly decreased by statin therapy. These results suggest that statins are substantially more efficacious for lowering remnant cholesterol than would be projected based on their ability to lower triglycerides. If the cardiovascular risk reflected by triglycerides is due to remnant cholesterol rather than triglycerides per se (14,35), then our results indicate cardioprotective benefits of statins beyond LDL-C lowering and suggest broader indications for statins in treating remnant hyperlipidemia. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The fatty acid composition of lipoprotein lipids vary greatly depending on the abundance of cholesteryl esters, triglycerides, and phospholipids (36). In accordance with linoleic acid being the primary constituent of cholesteryl esters—the dominant lipid in LDL particles—statin therapy led to the greatest lowering of this omega-6 fatty acid. Absolute levels of omega-3 fatty acids were only modestly decreased, in agreement with prior studies (12,37). These results are consistent with omega-3 fatty acids being primarily bound to the phospholipids, which only account for some 30% of the lipids in LDL particles (36). Monounsaturated and saturated fatty acids were decreased to a broadly similar extent as total triglycerides and phospholipids, respectively, which is coherent with the main fatty acid compositions for these lipid classes (36). The changes in the relative fatty acid balance due to statin therapy were modest. Although lower levels of the ratio of omega-6 fatty acids to total fatty acids have been associated with higher cardiovascular risk (5,38), evidence for a causal relation is lacking. The overall consistency between the genetic and longitudinal association patterns indicate that the various fatty acid modulations are on-target effects of HMGCR inhibition rather than due to cholesterol independent properties of statins (37). XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We also assessed whether statin therapy would be associated with biomarkers in various non-lipid
pathways. (Glycoprotein acetyl) GlycA, a measure of systemic inflammation and a biomarker for CVD and all-cause mortality (5,6,32,33,39), was modestly lowered, in accordance with the proposed anti-inflammatory properties of statins (7,8). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, both longitudinal and genetic analyses provided no evidence for substantial effects of statins on amino acids, glycolysis and gluconeogenesis metabolites, and ketone bodies. Several metabolites in these pathways have recently been shown to be risk markers for CVD and type 2 diabetes (5,6,17,21,31). Although the potential causal roles of these biomarkers remain unclear, our results suggested that statin therapy would not be efficacious for lowering the cardiometabolic risk associated with these markers. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; High-throughput metabolomic profiling in large cohorts with multiple time points and genetic information elucidated the pharmacological effects of statins on lipoprotein subclasses including their lipid constituents and fatty acid composition. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These results suggest a more efficacious role of statins for lowering remnant cholesterol levels than would be expected based on the ability of statins to lower circulating triglycerides. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The absence of robust associations of statin use with circulating amino acids, glycolysis and gluconeogenesis metabolites, and ketone bodies suggest minimal pleiotropic effects on these non-lipid biomarkers. As a corollary, statin therapy appears to have little or no efficacy on these novel markers of cardiometabolic risk. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The exquisite match between the metabolic association patterns from observational and genetic analyses serves as a proof of concept, illustrating how the combination of metabolomics and genetic proxies for drug mechanisms can facilitate the assessment of pharmacological action and on-target effects for known therapies and novel drug targets. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although Mendelian randomization of drug targets has been used previously (19,20,34), our study was
the first to our knowledge to combine the concept with observational results across a wide range of cardiometabolic biomarkers. As extensive metabolomics and genetic data are increasingly becoming available in large biobanks, such comprehensive molecular profiling can augment drug development in both preclinical and clinical trial stages to elucidate molecular mechanisms, clarify pleiotropic effects, and inform treatment indication. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">22</td>
<td class="data">Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review</td>
<td class="data">THE WAY FORWARD =&gt; The global challenges of diet-related obesity, diabetes, and CVD present enormous health and economic burdens (404) and emphasize the imperative of prioritizing nutrition in clinical care, advocacy, research, and policy. Scientific advances provide a wealth of new evidence on the key dietary priorities for cardiometabolic health. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These include food-based priorities for more fruits, non-starchy vegetables, nuts, legumes, fish, vegetable oils, yogurt, and whole grains; and fewer red meats, processed (sodium-preserved) meats, and foods higher in refined carbohydrates and salt (Figure 3). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Red meats should be minimized to prevent diabetes; butter used occasionally but not emphasized; and other foods (e.g., unprocessed poultry, eggs) consumed in moderation according to personal preference. Coffee and tea can be enjoyed, with possible (but not yet confirmed) benefits; and alcohol, if consumed, should be moderate (up to 1 drink/day for women and 2 drinks/day for men). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Harmful additives, in particular sodium, trans fat, and added sugar, will generally be lower in such diets and must be further minimized through strong policy actions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX There is growing evidence and consensus for such food-based dietary patterns as the best means to reduce CVD, obesity and weight gain, and diabetes, (21) replacing outdated emphases on total fat, other isolated nutrients, or calorie counting. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">23</td>
<td class="data">Biomarkers of rapid chronic kidney disease progression in type 2 diabetes</td>
<td class="data">In this study of individuals with type 2 diabetes and CKD3 we found that within a large set of candidate and global discovery biomarkers, at least 62 showed some evidence for association with subsequent rapid renal function decline. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Many of these biomarkers showed high correlations with each other and with clinical covariates so that a much sparser set of 14 biomarkers contained most of the predictive information beyond clinical covariates. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found that the increment in prediction with these biomarkers was of sufficient magnitude that it would be useful for risk stratification into clinical trials. Some of the biomarkers identified in the most predictive panels are already known to be associated with eGFR (that is, β2-microglobulin and cystatin-C), whereas others have little or no prior data (for example, SDMA/ADMA ratio, FGF-21, and uracil). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The best biomarker panel for prediction consisted of the restricted clinical covariates along with 35 biomarkers; however, this was only modestly better than the best sparsemodel that only required measurement of 14 biomarkers. The expense and logistics associated with validation and subsequent utilization of any new panel means that the 14 biomarker panel represents a more pragmatic approach. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This panel of biomarkers now warrants further evaluation in other cohorts. We used clinical creatinine measurements to calculate eGFR in this study, and as there is considerable variability in this measure, it is unsurprising that the in-sample measure of creatinine was also selected in our biomarker panels. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Space does not permit a detailed discussion of each of the 14 biomarkers selected and some of the associations have been described elsewhere. (5,6) Here we focus on some of the more novel associations. One of the strongest predictive biomarkers in our study released during proteolytic breakdown of nuclear proteins and both have been studied as biomarkers for cardiovascular disease (CVD) (7–9). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SDMA is primarily excreted via the kidney and is strongly associated with renal function, (7) but there is also some evidence that the protein methyl-transferase PRMT5 that synthesizes SDMA regulates interleukin-2-gene expression, (10) suggesting that higher levels of SDMA might also reflect inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We did not find any association of SDMA with inflammatory biomarkers such as C-reactive protein, but there was a positive correlation (rho = 0.39) with interleukin-2 receptor α levels. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, rather than a bioactive effect of SDMA itself, the observed prediction in our study may simply indicate that SDMA accumulates when filtration falls and thus it is predictive because it is a good biomarker of filtration. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to SDMA we found that ADMA was only weakly inversely correlated with eGFR but more strongly correlated with arginine. The ratio may be a biomarker of these complex interactions and we note that was the ratio of SDMA/ADMA. SDMA and ADMA are models including the ratio yielded higher AUROCs than models including ADMA and SDMA separately. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX KIM-1 is a protein expressed on the apical membrane of proximal tubule cells. Its ectodomain is shed into the lumen and serves as a urinary biomarker of kidney injury, although there have been mixed results for it as a prognostic biomarker in diabetic kidney disease, (11,12). Studies have shown that KIM-1 expression is increased in the glomerulus in diabetic animal models (13) and is elevated in their plasma (14). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recently, it was reported that shed KIM-1 also serves as a blood biomarker of kidney injury in humans, as plasma KIM-1 levels were higher in patients with acute kidney injury than in healthy controls or postcardiac surgery patients without acute kidney injury (2). In that study serum KIM-1 level at baseline in type 1 diabetes patients strongly predicted rate of eGFR loss and risk of ESRD during 5–15 years of follow-up. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We identified associations with rapid progression of two fibroblast growth factor members FGF-21 and FGF-23. FGF-21 is a 181 amino acid polypeptide secreted predominantly by the liver and adipose tissue and has been shown to play an important role in lipid and energy metabolism (15,16). Previous studies have reported cross-sectional associations with eGFR (17). Median serum FGF-21 levels were  &gt; 7–15-fold higher in dialysis patients than controls (18,19) but fell after short-term angiotensin blockade (19). In cross-sectional studies FGF-21 levels were also elevated with albuminuria even when eGFR was  &gt; 60 ml/min (20). FGF-21 was independently associated with urinary albumin in type 2 diabetes (20). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The kidney has relatively low levels of FGF-21, (21) and FGF-21 activity depends on the tissue-specific expression of its cofactor Klotho β that is predominantly in the liver and adipose tissue rather than the kidney. Thus, association between FGF-21 and renal disease progression may reflect simple accumulation in renal disease. However, it might also reflect an antifibrotic response; it was shown that FGF-21 prevented the expression of profibrotic cytokines, including transforming growth factor-β1 in the kidney (22). XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX FGF-23 is a 32-kD bone-derived hormone with several known endocrine functions in the kidney, including the promotion of urinary phosphate excretion and the inhibition of the hydroxylation of 25-hydroxyvitamin D (23). Elevated FGF-23 was an independent risk factor for ESRD in patients with relatively preserved kidney function and for mortality across the spectrum of CKD (24). XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recently, it was shown in 13,448 subjects of the Atherosclerosis Risk in Communities study (ARIC) that higher serum level of FGF-23 were associated with increased risk of incident ESRD, independent of the baseline level of kidney function and a number of other risk factors (25). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX C16-acylcarnitine was one of the strongest predictors of rapid progression in our study. Previously in the KORA cohort, acylcarnitines and especially the ratio of serine to glutarylcarnitine were associated with eGFR, (26) and in FinnDiane study urinary acylcarnitines were associated with</td>
</tr>
<tr>
<td class="r data">24</td>
<td class="data">Contributions of risk factors and medical care to cardiovascular mortality trends</td>
<td class="data">As we have reviewed, since the middle of the 20th century, there has been attention to trends in CVD deaths, and a desire to understand its drivers. We found that with the exception of the well-designed and carefully executed MONICA Project and a few other within- or cross-country studies, most analyses of the role of risk factors or treatment in CVD mortality trends relied on qualitative observations or basic quantitative tests of whether the two variables changed together, with limited attention to other explanations for the decline. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This seemingly critical assessment is however at least partly an outcome of both the changing epidemiological and clinical knowledge on CVD causes and treatments and of the changing nature of CVDs themselves. All of the major empirical studies on determinants of CVD mortality decline collected data over a period in which many aspects of CVD aetiology and survival were changing rapidly in high-income countries: partially correlated trends in some risk factors and opposite trends in others; changes in demography of people with CVD events with average age increasing and changes in sex composition of CVD events and deaths (issues that MONICA was less able to capture given that it did not assess people over 65 years old and that fewer of the events were in women than in men); and dramatic changes in how AMI was defined, diagnosed, and treated with increased awareness on the part of physicians and the general public about symptoms and the importance of early in-hospital treatment, increasingly sensitive biomarkers capable of detecting minor events that would not be captured by symptoms alone or the electrocardiogram, and uptake of more effective treatments both at the hospital and among survivors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As a result of the multiplicity of other changes, measured and unmeasured, over this period, and the paucity of high-quality longitudinal population-based data (many of which had been proposed at the Bethesda Conference but were not pursued), the answer to the question of what set into motion the decline in mortality, and the relative roles of treatment and prevention, is likely to remain largely correlational and somewhat speculative, rather than causal. Despite these limitations, the vast body of research on CVD mortality trends also allows some conclusions with some confidence:  XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, in high-income countries and in some middle-high-income countries in Latin America, once the CVD mortality decline began, it never stopped or even slowed down, a situation that was hard to envision in the 1970s and 1980s. Even today, there is little indication that the relative rate of decline in CVD mortality in high income countries is reducing; if anything, it is increasing proportionally in many countries. If current downwards trends continue, IHD and stroke will become uncommon causes of death under 70 years of age in high-income countries. Recent data and modelled mortality trends by WHO and others seem to indicate that currently middle-income and upper-middle-income countries have begun similar trends. This decline in turn will lead to an increase in longevity and life expectancy, because CVDs are a major cause of mortality worldwide. (213) XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, trends since the 1970s have almost certainly benefited from a mixture of continued declines in key behavioural risk factors such as smoking; in physiological risk factors such as blood pressure and serum cholesterol, part of which is likely to be due to changes in diet (e.g., lower intake of salt and saturated fats, and year-around availability of fruits and vegetables), and due to widespread use of effective pharmacological treatments for hypertension and dyslipidaemia; and in improvements in acute care including time before reaching hospital, better diagnosis, and acute care. Blood pressure seems to have been declining for an even longer time in high-income countries, a phenomenon whose drivers are not known but which may have been responsible for the much earlier start of the decline in stroke mortality compared to IHD. While the contributions of both risk factors and treatments to the decline in CVDs is likely real, none of the measured drivers explains the similarities and differences across countries or between men and women in when the decline began. (184) This leaves room for hypotheses related to other phenomena – related to subtle changes in diet or health systems, to reductions in infections and resulting inflammatory response, and to improved fetal and childhood nutrition and health – as possible determinants of the decline. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, the nearly universal increase in adiposity does not seem so far to have attenuated the long-term declining trend of CVD mortality in high income countries since the 1960s. It may be that the rate of decline in these countries might have been even steeper if the obesity epidemic had not occurred, but to date the correlation and the magnitude of such an effect seems modest (see Figure 8). (168, 189) This contrast with the relatively important effect of obesity in individual-level epidemiological studies may have been partly due to more aggressive management of physiological risks that mediate the effects of adiposity among overweight and obese people, (190) leading to a “decoupling” of BMI from blood pressure and lipids (but not diabetes) both across populations and in individuals. (175, 191) Nevertheless in low-income countries, where maternal and child under-nutrition are still widespread and where the thinly stretched healthcare system may be unable to screen and treat physiological risk factors, (304) rising rates of obesity might result in increased population risk of CVDs beyond the relatively modest impacts in high-income countries; reliable mortality trend data to better envision this possibility are however not available. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, whatever the explanations for a century of rise and fall in CVD mortality in the high-income world, former communist countries in Central and Eastern Europe, defy their universal generalisation. The extraordinary patterns of change in these countries appear to be closely synchronised with massive political and social changes following the collapse of communism starting in the early 1990s. Although an important role for hazardous alcohol drinking has been identified, especially in Russia, there remains an uncertainty about the precise mechanisms involved. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
CONCLUSIONS =&gt; While a fully comprehensive and convincing account of the precise drivers of the declines we have described in CVD for many countries remains elusive, we return to the fact that these declines are enormous and are making important contributions to improvements in life expectancy in most regions. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For some countries and populations, therefore, it is perhaps reasonable to argue that whatever the drivers of the decline in CVDs, the continued impressive pace of decline should be a reason to give more attention to other health conditions that are either not declining as fast or rising such as cancers, diabetes and neuro-psychiatric conditions. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">25</td>
<td class="data">Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people</td>
<td class="data">This population-based, contemporary study of nearly 2 million individuals with a median follow-up of 5·5 years provides strong evidence that associations between type 2 diabetes and 12 specific cardiovascular disease outcomes differ in terms of direction and magnitude of effects. Our findings draw attention to the high absolute and relative risks of incident peripheral arterial disease, heart failure, and stable angina in people with type 2 diabetes, (1, 11) diseases that differ in preventive strategies and that often are poorly represented in the primary endpoint of randomised trials. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Peripheral arterial disease is one of the most common first presentations of cardiovascular disease, consistent with the increase in prevalence between 2000 and 2010  reported in a systematic review. (14) Furthermore, of the 12 diseases studied, peripheral arterial disease showed the strongest association with type 2 diabetes, with an adjusted HR of 2·98 (95% CI 2·76–3·22), consistent  with previous studies. (14) XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Heart failure was also one of the most common first presentations (accounting for 14·4% of events in people with type 2 diabetes). Our definition excludes heart failure occurring after acute myocardial infarction, but we have to interpret this result with caution because we know that our data sources miss some cases of myocardial infarction. (15) Possible mechanisms might include long-term hypertension, chronic hyperglycaemia, microvascular disease, glycosylation of myocardial proteins, diabetic nephropathy, and autonomic neuropathy. (1)  Similar to the meta-analysis of cohort studies in the Emerging Risk Factors Collaboration, (4)  we noted a weaker association of cardiovascular disease with type 2 diabetes in people 60 years or older than in younger people. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A novel finding was the association of type 2 diabetes with reduced incidence of two major aneurysmal diseases: abdominal aortic aneurysm and subarachnoid haemorrrhage. An inverse association between diabetes and abdominal aortic aneurysm has been suggested by cross-sectional studies of abdominal aortic aneurysm screening and case-control studies, (6, 16, 17) but evidence from large prospective cohort studies has been mixed. (18,19) With 3113 abdominal aortic aneurysm events, our study is one of the largest cohort studies investigating this outcome, (18,19) and makes a substantial contribution to the evidence for a possible causal relation. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX No previous cohort study has been large enough to investigate the association of type 2 diabetes with subarachnoid haemorrhage, but several case-control studies are consistent with our results (panel). (20) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These findings support the need to identify potential mechanisms that might have therapeutic implications. Such mechanisms might include diabetes-mediated changes in the vascular extracellular matrix, such as glycation of the extracellular matrix and covalent cross-linking between elastin and collagen in the aortic wall. (21) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several studies have shown that type 2 diabetes is associated with out-of-hospital cardiac arrest and sudden cardiac death, (22,23) and an important unanswered question has been the extent to which this effect is mediated by incident diseases known to increase arrhythmic risk such as myocardial infarction and heart failure. In this study we looked at the initial presentation of cardiovascular disease—ie, arrhythmia with no previous myocardial infarction or heart failure—and our finding of no association suggests that the higher risk of cardiac arrest with type 2 diabetes is mediated by atherosclerotic coronary disease. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sex differences in the effect of diabetes on coronary heart disease have been the subject of several reviews and meta-analyses. (24) Although the absolute risk for coronary heart disease morbidity and mortality is lower in women than in men, the relative risk associated with diabetes has generally been reported to be higher in women, (7,25,26) potentially due to their adverse risk-factor profile. (26) The most recent meta-analysis of prospective studies focusing on diabetes reported relative risks for incident coronary heart disease of 2·63 for women and 1·85 for men with diabetes. (7) XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Sex differences in the association of type 2 diabetes with outcomes other than coronary heart disease have less often been reported, with conflicting results for stroke. (27,28) In participants younger than 60 years, we noted weak evidence of a slightly stronger association of type 2 diabetes with myocardial infarction in women than in men—which is consistent with previous reports—but no other sex differences in associations between type 2 diabetes and cardiovascular outcomes. (24) XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our finding that HbA1c concentrations were associated with the risk of many cardiovascular diseases strengthens the case for the causal relevance of blood glucose in type 2 diabetes-related cardiovascular disease. These associations were particularly strong for peripheral arterial disease, and persisted even in participants with an HbA1c concentration of less than 48 mmol/mol (6·5%), suggesting that risk is not controlled in this group. Individuals in whom HbA1c had not been measured were at higher risk, consistent with measurement being a marker of overall quality of care. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our results support the use of clinically collected realworld cohorts from electronic health records to provide such evidence of absolute and relative risks of different disease outcomes in people with type 2 diabetes, and to complement findings from conventional investigator-led cohort studies, (4) which typically are smaller, not contemporary, and have less external validity. Our results will help to inform drug development and the design of trials in type 2 diabetes. Trials (3)  have often included acute myocardial infarction and acute stroke as their primary event endpoints, because of a previous perception that these outcomes were the main disease burdens in type 2 diabetes, or that they are easier to ascertain and validate than chronic disease endpoints. We propose that chronic disease endpoints such as heart failure, peripheral arterial disease, and stable angina are important to consider in the choice of primary endpoint because they are common, have a high morbidity burden, and might have different treatment effects from myocardial infarction or stroke.  XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PANEL: RESEARCH IN CONTEXT =&gt; SYSTEMATIC REVIEW =&gt; We did a scientific literature search for population-based cohort studies that examined the association of two or more incident cardiovascular diseases in people with and without type 2 diabetes. We searched Embase and Medline for articles in English published within the past 10 years using the search terms “diabetes”, “occur*” or “association” or “incidence” or “onset” or “risk”, “prospective” or “cohort”, and terms for each of the individual diseases of interest as well as general terms for cardiovascular disease. We found a large metaanalysis of 102 cohort studies by the Emerging Risk Factors Collaboration, (4)  and meta-analyses of sex differences in the associations of diabetes with stroke (27) and coronary heart disease. (7)  These meta-analyses did not differentiate between type of diabetes, and studied only a few cardiovascular diseases (coronary artery disease, stroke, vascular death). We found no cohort studies that reported the distribution of a large number of different initial presentations of cardiovascular disease in patients with type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX INTERPRETATION =&gt; Our study builds on the findings of previous cohort studies and meta-analyses showing that diabetes is strongly associated with increased risk of many atherosclerotic cardiovascular diseases. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We show that this specifically holds true for type 2 diabetes, and that peripheral arterial disease and heart failure are the most common initial presentations of cardiovascular disease in patients with type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We corroborate previous smaller studies in showing that type 2 diabetes is associated with reduced risk of abdominal aortic aneurysm and possibly subarachnoid haemorrhage. These findings have implications for disease modelling and clinical risk assessment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">26</td>
<td class="data">Ethnic variation in the activity of lipid desaturases and their relationships with cardiovascular risk factors in control women and an at-risk group with previous gestational diabetes mellitus: a cross-sectional study</td>
<td class="data">Lipid desaturase enzymes have a wide tissue distribution and we evaluated desaturase activities on the basis of fatty acid compositions in a range of plasma lipid pools. Fatty acids in the FF pool would be expected to reflect adipose tissue metabolism, being largely the product of adipose tissue lipolysis and there is previous evidence for this with respect to SCD-16, SCD-18 and D5D activities [15]. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the TG pool, fatty acids would be expected to reflect fatty acid metabolism in the liver (following VLDL secretion) and be influenced by both recent meal content and by endogenous metabolism. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fatty acids in the CE pool would also be expected to reflect hepatic metabolism, but would relate to diet over preceding weeks to months. The fatty acid composition of the PL pool is more difficult to interpret [15] and it is, therefore, of interest that there were strong correlations between desaturase activities derived from CE and PL pool fatty acid compositions. Moreover, in general, ethnic differences in desaturase activities and associations between desaturase activities and metabolic risk factors were most apparent when desaturase activities were calculated from the fatty acid compositions of the CE and PL pools. Nevertheless, with standardization for potential confounders, lower SCD-16 activity was apparent in all pools in African Caribbean and Asian Indian women relative to white Europeans. Similar, though slightly less consistent differences were seen with SCD-18 activity. Overall, these observations strongly support the conclusion that white European women have higher SCD activity than Asian Indian or African Caribbean women. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Genetic variation has been reported in Scd-1 [16] but differences in polymorphism frequencies between Asian Indians, African-Caribbeans and white Europeans do not appear to have been described. We found D6D activity to be significantly lower in Asian Indian women relative to white Europeans. D6D metabolises the first step in conversion of the essential fatty acids linoleic (18:2 n-6) and alpha linolenic (18:3 n-3) to longer chain, polyunsaturated fatty acids and our observations are consistent with the proposal that reduced D5D activity might be responsible for lower polyunsaturated fatty acid concentrations in Asian Indians [17]. Genetic variation might underlie the lower D6D activity in Asian Indians but definitive studies of ethnic variation in the Fads2 gene that codes for D6D have yet to be carried out. D5D activity was significantly higher in African Caribbean women relative to white Europeans. D5D metabolises eicosatrienoic acid to arachidonic acid and higher arachidonic acid levels have been reported previously in people of Black African origin [18]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recent evidence has confirmed an association between high levels of C16 and C18 saturated fatty acids in the plasma PL pool and increased risk of CHD and between high levels of n-6 polyunsaturated fatty acids and decreased risk of CHD [21]. The relatively low SCD activity in Asian Indian women might be expected to be associated with higher C16 and C18 fatty acid levels and the relatively lower D6D activity with lower n-6 polyunsaturated fatty acid levels. Both characteristics we identified in Asian Indians would, therefore, accord with their elevated risk of CHD. However, no such consistencies could be inferred with regard to the relatively low risk of CHD in African Caribbean women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Independently of ethnicity, SCD-16 activity was positively associated with BMI, waist circumference and serum triglycerides. Positive associations between SCD activity and adiposity have been reported previously [13,14], and a positive association with serum triglyceride concentrations is well-documented [11,22]. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The independent associations we observed between D6D and D5D activity and risk factors were generally similar to those described by others [13,15], with positive associations between D6D activity, adiposity and triglycerides and negative associations between these risk factors and D5D activity. Previous studies have found a positive association between insulin sensitivity and D5D activity, calculated from skeletal muscle phospholipid composition [23,24] but we found little evidence for associations between desaturase activities calculated from plasma fatty acids and either glucose levels or insulin sensitivity. The single positive association noted between insulin sensitivity and D5D activity derived from fatty acid ratios in the TG pool and may have been a chance finding. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX With regard to ethnic variation in risk of T2DM, it could be speculated that the lower SCD activities in African Caribbeans and Asian Indians might contribute to increased levels of saturated fatty acids, increased levels of which may be associated with increased risk of T2DM [25,26]. However, given the overall lack of association between diabetes risk factors and desaturase activities, it seems unlikely that ethnic variation in desaturase activity contributes to ethnic variation in risk of T2DM.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; Despite low SCD activities in African Caribbeans and Asian Indians possibly contributing to a tendency to higher C16 and C18 saturated fatty acid levels, it seems unlikely, given the absence of any association between desaturase activities and plasma glucose concentrations or insulin resistance, that ethnic variation in desaturase activities contributes to ethnic variation in risk of T2DM. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similarly, variation in desaturase activities showed no consistency with the lower risk of CHD in African Caribbeans. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, the relatively low D5D activity we observed in Asian Indian women suggests a contribution from lower desaturase activities to the higher risk of CHD in Asian Indians. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">27</td>
<td class="data">alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population</td>
<td class="data">Using a non-targeted biochemical screening approach in a large and well characterized cohort of non-diabetic subjects representing a wide spectrum of insulin sensitivity, we identified a–hydroxybutyrate (a–HB) as a biomarker segregating with clamp-derived IR in subjects with normal glucose tolerance. Furthermore, a–HB segregated with dysglycemia (IFG+IGT) independently of, and in
addition to, IR. Importantly, these associations were independent of sex, age, and BMI. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thus, together with other biomarkers, a–HB may provide a diagnostic tool to identify IR and/or IGT earlier than currently used clinical tests. a–HB is an organic acid derived from a-ketobutyrate (a–KB) (Figure 7). a–KB is produced by amino acid catabolism (threonine and methionine) and glutathione anabolism (cysteine formation pathway) and is metabolized to propionyl-CoA and carbon dioxide [25]. a–HB is formed as a by-product during the formation of a–KB via a reaction catalyzed by lactate dehydrogenase (LDH) or a–hydroxybutyrate dehydrogenase (a–HBDH) (Figure 7), an LDH isoform present in the heart [26]. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Accumulation of a–HB is postulated to occur in vivo when either XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (a) the formation of a–KB exceeds the rate of its catabolism, which leads to substrate accumulation, or XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (b) there is product inhibition of the dehydrogenase that catalyzes the conversion of a–KB to propionyl-CoA [25,27]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX a–KB is also produced as a result of the conversion of cystathionine to cysteine. Under conditions of increased oxidative stress, a higher flux of cysteine into production of glutathione, the primary antioxidant in cells, occurs from a shift in homocysteine production from transmethylation of methionine to transsulfuration of homocysteine to produce cystathionine [28] (Figure 7). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In one report, a–HB was associated with excess glutathione demand and disrupted mitochondrial energy metabolism and shown to derive from hepatic glutathione stress [28], supporting the idea that elevated a–HB may be associated with increased oxidative stress in the IR state. a–HB may become elevated by at least two mechanisms:  XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) elevation of hepatic glutathione stress resulting in an increased demand for glutathione production, and XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) elevation of the NADH / NAD + ratio due to increased lipid oxidation. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The first mechanism likely contributes to increased a–HB formation by supplying more a–KB substrate from increased cysteine anabolism (Figure 5). Consistent with this interpretation, we observe statistically significant elevation of both a-KB and cysteine with increasing insulin resistance from the global screening data (Figures 2 &amp; 5, Table 2), similar to the trend observed with a-HB. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In support of the second proposed mechanism, increased lipid oxidation is a metabolic feature of IR, and is indexed by the insulin-inhibited FFA concentration [7,14]. Our finding of a positive association between steady state FFA and plasma a–HB concentrations in the whole cohort supports the possibility that an increased NADH/NAD + ratio favors reduction of a–KB to a–HB (Figure 7). XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Changes in other important IR-associated metabolites within metabolic pathways leading to the formation of a-KB and a-HB are highlighted in Figure 7. For example, reduced levels of glycine (Figure 6E) and serine upstream of a-KB formation may be consistent with increased gluconeogenesis which is observed with IR in db- / db- mice [29]. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our interpretation that a redox imbalance may contribute to elevated a-HB in the context of IR is consistent with our finding that branched-chain alpha-keto acids, such as 3-methyl-2-oxobutyrate, are elevated with IR (Table 3). These increases may be due to the effect of the redox imbalance on the directionality of the dehydrogenases that reduce / oxidize these keto acids (Figure 7). In addition, a-HB has also been observed to be elevated in T2D subjects and animal models of T2D, as well as in severe lactic acidosis and ketoacidosis [25, 27, 30, 31, 32, 33, 34]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Interestingly, in normal subjects and T2D patients, it has been shown that restoration of the NADH / NAD + redox balance by glutathione infusion therapy resulted in improvement of insulin sensitivity and b-cell function in normal subjects and in T2D patients [35]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a recent study comparing the urinary profiles of 98 intermediary metabolites measured by targeted MS in 74 obese and 67 lean individuals, Newgard et al. identified a metabolic signature for the accumulation of branched-chain amino acids, the glutamine / glutamate couple, several acylcarnitines, and some aromatic amino acids (phenylalanine and tyrosine) using principal component analysis [36]. These metabolites were also related to insulin resistance (as determined by the HOMA index) and interpreted as marking the metabolic consequences of excessive fat and protein intake, with impairment of insulin signaling and mitochondrial overload. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is noteworthy that in the non-targeted metabolomics approach of the present study, lipid molecules, branched-chain amino acids, and acylcarnitines were also featured among the top 30 metabolites that RF analysis associated with the M value (Figure 2). The current data narrow down the complex interactions of amino acid and lipid metabolism [37] to highlight the importance of a single marker, a–HB, which may reflect oxidative burden in the context of IR. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX With an unmet need for a practical clinical test that accurately measures IR in individuals, identification of a–HB as a significant biomarker for separating IR from IS subjects using a fasting plasma sample could lead to development of such a diagnostic test. a–HB in combination with other biochemical and clinical parameters may also prove to be useful as a clinical indicator of subclinical abnormalities of glucose metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">28</td>
<td class="data">Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury</td>
<td class="data">Although emerging metabolomics profiling technologies hold enormous promise for illuminating biology, applications to human disease are still lacking. We therefore chose a clinical model of MI that allows for precise kinetic analysis in patients who served as their own controls. This experimental design markedly enhanced our power to identify statistically meaningful changes, while the targeted MS platform, in which metabolites are analyzed with high sensitivity and structural specificity, allowed us to unambiguously identify metabolites and thus avoid potentially confounding clinical variables (7). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We hypothesized that small biochemicals may leak from injured myocardial cells before cellular damage would permit egress of macromolecules, potentially allowing for earlier detection of disease (28). XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Presently used indicators of myocardial injury (i.e., the myocardial isoform of CK-MB and cardiac troponins) reflect leakage of cardiac enzymes or structural proteins from irreversibly damaged cardiomyocytes, and are not reliably detected until at least 4 hours after myocardial injury (16). In contrast, the metabolic changes we identified in the PMI derivation cohort were readily apparent as early as 10 minutes after injury and were serially validated in distinct clinical cohorts. Coronary sinus catheterization provided the opportunity to sample directly from the organ of interest and served as another layer of validation that underscored the biological plausibility of the observed association between metabolic changes and MI. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, metabolite changes observed in humans modulated the response to hypoxic injury in vitro, which suggests that these metabolites not only serve as markers, but may also modulate the evolving response to ischemia in vivo XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The metabolic, structural, and functional consequences of ischemia and/or reperfusion have been examined in a wide variety of experimental animal models, including regional ischemia after coronary vessel occlusion in dogs (29–31) and swine (32–35) as well as in humans with coronary disease (36–40) or undergoing heart surgery (41–43). However, prior studies have generally assayed relatively limited subsets of metabolites in focused approaches. Some prior studies have also relied on invasive instrumentation, such as the implantation of dialysate catheters into the myocardium (32). In support of the applicability of a targeted liquid chromatography–MS (LC-MS) platform to human cardiovascular disease, we confirmed changes in metabolites that had been previously reported as appearing in either plasma or effluent from isolated, perfused hearts (32). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These changes included the sequential purine degradation products (ADP, AMP, inosine, hypoxanthine, and xanthine), intermediates of anaerobic glycolysis (lactic acid) and the TCA cycle (succinic acid), and amino acids known to be concentrated within cardiomyocytes (taurine and glutamic acid) (32). Analysis of patient plasma using a comprehensive LC-MS platform also identified additional metabolites in these pathways that had not to our knowledge been previously reported, such as the TCA cycle intermediates malic acid and aconitic acid. We have also identified what we believe to be novel changes in human plasma levels of pyrimidine metabolites, including orotic acid, malonic acid, and aminoisobutyric acid. Alterations in (trimethlylamine-N-oxide) TMNO, in contrast, suggest injury-mediated modulation of dietary compounds in the plasma. The platform also identified the stable circulating derivative of the proinflammatory metabolite of histamine, methylhistamine (44). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX While the application of metabolomics directly to humans has important advantages, functional studies must be pursued in complementary model systems. Our in vitro studies identified roles for several of the metabolites discussed above, including roles for glycerol-3-phosphate and malonic acid in diminishing hypoxia-triggered apoptosis in cardiomyocytes.  From a clinical perspective, metabolic responses arising uniquely from an abnormal hypertrophic myocardial substrate or the direct effects of ethanol must be considered; these could potentially restrict broader application to general populations. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Ultimately, the validation of our findings in SMI patients mitigates the concern that ethanol-induced thrombosis and downstream injury generates a different metabolic profile from infarction as a result of coronary plaque rupture. Complementary studies of other body fluids, particularly urine, may also provide insight into metabolites that are rapidly cleared from the circulation. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is unlikely that the metabolic changes we observed herein are attributable to medication exposures. Aspirin, beta blockers, and heparin were used almost uniformly in each of the cohorts studied (Table 1), removing them as potential confounders. When subjects were stratified by calcium channel blocker or statin use, no significant differences in metabolic responses were observed for any of the metabolites in Tables 2–5 (P &gt; 0.05 for each). XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The recognized advantages of coupling LC with targeted MS / MS analysis include greatly increased sensitivity and highly specific identification of analytes. Targeted MS methods provide absolute measurement of analyte concentrations when appropriate standards are added, as we demonstrated in the present study. A targeted approach, however, is blind to changes in metabolites whose retention times and MS characteristics have not been incorporated into the analysis method. As efforts to define the human metabolome grow (25), we anticipate increasingly comprehensive targeted platforms for biomarker and pathway discovery. We previously reported initial observations of the application of a more limited LC-MS/MS–based platform (10), in which many of the analytes had not been unambiguously identified, to patients undergoing cardiac exercise testing. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Both the present work and the prior study detected circulating purine breakdown products, including hypoxanthine, which may not always be of cardiac muscle–specific origin. However, even with deletion of hypoxanthine from the composite score, the remaining 3 metabolites (aconitic acid, TMNO, and threonine) derived from the PMI subjects have excellent discrimination of SMI cases from controls, with AUC of 0.83. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We hypothesize that in certain clinical contexts, such as myocardial ischemia at rest, elevations in hypoxanthine would be informative. In contrast, in the setting of vigorous exercise or diffuse muscle injury, the specificity of hypoxanthine for myocardial injury would be diminished. The present results also suggested the modulation of a distinct subset of TCA cycle intermediaries, amino acids, and amines not observed in the exercise cohort, which may reflect differences in the human models or distinct metabolic signatures of myocardial ischemia and MI. Ultimately, the integration of multiple data sets will be necessary for large-scale validation in patients to identify plasma biomarkers of myocardial ischemia and early injury, for which no circulating biomarkers currently exist (45). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In summary, we demonstrated the application of a metabolomics platform to a carefully phenotyped patient cohort for the discovery of blood markers with the potential to detect the presence of very early myocardial injury. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We identified abnormalities in circulating metabolites as soon as 10 minutes after myocardial injury, a time frame in which, to our knowledge, no currently used biomarkers are elevated. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">29</td>
<td class="data">Lipids and glucose in type 2 diabetes: what is the cause and effect?</td>
<td class="data">From an initial perception that a disorder of glucose metabolism was the primary event in the pathogenesis of type 2 diabetes, there is now a growing appreciation that chronic elevation of FFA levels is an early event that contributes to the development of this disease. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX FFAs induce insulin resistance, which increases with FFA levels, and this can be a beneficial adaptive response during starvation and pregnancy. However, insulin resistance can become counterproductive when there is an excess of energy intake associated with physical inactivity. The extra fuel is stored in visceral and subcutaneous fat depots. As fat accumulates, there is an ongoing increase in the levels of plasma FFAs, which causes insulin resistance. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, the deficit of another product of adipose tissue (e.g., adiponectin) may contribute to increased insulin resistance. To counter insulin resistance and prevent hyperglycemia, insulin levels increase. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In individuals with a genetic predisposition for diabetes, however, the pancreas cannot compensate for the increased secretory demands placed on it, resulting in type 2 diabetes. The pivotal role of FFAs in the development of insulin resistance and type 2 diabetes suggests that the optimal therapeutic intervention should decrease plasma FFA levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The PPAR family is intimately involved in lipid metabolism. Two subtypes of these receptors are the site of action of synthetic PPAR agonists: PPAR-a and PPAR-Y. The former increases fatty acid oxidation, whereas the latter results in the redistribution of fat from visceral to subcutaneous body fat and an increase in adiponectin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The outcome of activation of PPAR-Y is a lowering of plasma FFA concentrations and improved insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The effects of PPAR-a on lipid metabolism may also bring about improvements in insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The currently available PPAR agonists selectively activate either PPAR-a (i.e., fibrates) or PPAR-Y (i.e., TZDs) and have been shown to improve lipid metabolism. It may be that dual agonism with PPAR-a/Y agonists will provide additional benefits above and beyond those achieved with sole activation of either PPAR-a or PPAR-Y. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
</tbody>
</table>
</div>
</div>
</body>
</html>
